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“Reality is not always probable, or likely”  
― Jorge Luis Borges  
  
  
ABSTRACT 
The overall survival of breast cancer patients has increased quite remarkably in the past 
decades in the developed countries due to substantial improvements in diagnosis and 
treatment. As a consequence, the proportion of women alive after a breast cancer diagnosis is 
currently increasing. It is therefore becoming of outmost importance to also focus on 
medium- and long-term health outcomes of women with breast cancer. 
Swedish population registers were used to study time-dependent survival of breast cancer 
patients according to age and tumor characteristics for the following health outcomes: causes 
of death, distant metastasis, risk of hospitalization due to a bone fracture, and risk of 
hospitalization due to an infection. Different survival analysis methodologies were applied 
including Cox regression models, Poisson regression models and flexible parametric survival 
models. Several measures were used to assess the outcomes of interest: rates, ratios and 
cumulative incidences. Comparisons with the general population using standardized 
incidence and mortality ratios were also performed. 
The risk of dying from breast cancer varied by age, and by tumor characteristics in a time-
dependent fashion. Circulatory system disorders were an important cause of death in our 
study population, in particular among women diagnosed with breast cancer after the age of 60 
years. The risk of distant metastasis was still non-negligible after five years from breast 
cancer diagnosis in most subgroups of patients. Women with breast cancer were at increased 
risk of being hospitalized with a bone fracture or with an infection for at least ten years since 
diagnosis. The risk of hospitalization due to an infection was particularly increased for skin 
infections and sepsis. Women with breast cancer were also at significantly increased risk of 
dying after being hospitalized with a bone fracture or an infection.  
Lymph node status at breast cancer diagnosis was not only found to be an important long-
term predictor of overall and disease-free survival, but also of risk of hospitalization due to 
bone fracture or infection. Women with estrogen receptors-negative breast tumors showed a 
worse overall prognosis as compared with patients with estrogen receptors-positive breast 
tumors only in the first five years after diagnosis. Estrogen-receptor positive tumors carried a 
low but persistent risk of distant recurrence and death. A breast tumor size of more than 
20mm at diagnosis was mainly associated with a worse short-term prognosis, however a mild 
significant association was detectable for more than five years from diagnosis. 
In conclusion, there is no evidence to support discontinuation of clinical follow-up in breast 
cancer patients. Further investigation on more targeted approaches for different subgroups 
should be considered and more attention to medical conditions not directly related to breast 
cancer would be probably beneficial for these women. Preventive measures for bone fractures 
and infections could be taken into more consideration for all breast cancer patients at 
increased risk. 
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1 INTRODUCTION 
Breast cancer is the most common malignancy in the female population worldwide and its 
prevalence is increasing in most countries. In the last decades there has been however a 
significant decrease in breast cancer mortality in many developed countries. This success is 
probably due to the effect of early diagnosis and particularly to the remarkable improvements 
in treatment. Incidence is instead still steadily increasing, possibly due to lifestyle and 
historical trends but probably also because of improved sensitivity of diagnostic approaches 
and procedures. These epidemiological trends translate into a general relevant increase of the 
number of women living with a previous breast cancer diagnosis. The better survival 
currently observed in many developed countries is now allowing the investigation of more 
long-term health outcomes in breast cancer patients, including those health outcomes that are 
not directly caused by or related to the disease. In particular, it would be interesting to shed 
more light on the type and timing of causes of death, distant recurrences and cause-specific 
hospitalizations according to different patient and tumor characteristics in order to assess the 
long-term behavior of some of the known prognosticators. This might also have implications 
on the way breast cancer patients are followed and monitored after the initial treatment period 
and it could also help clarify whether there is any evidence that the clinical follow-up can be 
modified or interrupted after some years in certain groups of patients. Another important 
question to address is whether certain subgroups of women with breast cancer are at 
increased long-term risk for bone fractures or infections and whether there is any need to 
consider more preventive care aimed at these two possible comorbidities. 
Finally, it is of potential interest to see whether some of these health outcomes occur more 
often as compared to the general female population from the same age, region and calendar 
period. Differences with the general population might underlie some inherent or acquired 
(e.g., treatment) characteristics of women who have been diagnosed with breast cancer 
influencing their overall survival and quality of life. We tried to give an overall picture of 
some of the relevant health outcomes in Swedish women with a previous diagnosis of breast 
cancer, and to study the time-dependent long-term effects of age and tumor characteristics. 
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2 BACKGROUND  
2.1 EPIDEMIOLOGY 
Breast cancer is the most common malignancy in the world and the second most common 
cancer overall in the female population, accounting for about 25% of all new cancer 
diagnoses. Breast cancer can also rarely affect males, but it is generally considered a 
malignancy mainly concerning the female population. In 2012, the global estimated amount 
of new breast cancer cases was 1,677,000, of which 794,000 occurring in the developed 
regions (of these, 367,000 in the European Union), and 883,000 occurring in the developing 
regions (Figure 1). In the period 2008-2012, there were about 6,255,000 breast cancer 
incident cases worldwide and 1,467,000 in the European Union. The incidence rates varied 
from the lowest estimate of 27 per 100,000 in Central Africa and Eastern Asia to the highest 
of 96 per 100,000 in Western Europe [1].  
 
Figure 1. Age-standardized incidence rates of breast cancer per 100,000 (adapted from 
GLOBOCAN 2012, IARC). 
Breast cancer is the world’s fifth cause of death from cancer overall with 522,000 deaths 
occurring in 2012. In developed countries it is the second most common cause of death due to 
a malignancy after lung cancer with 198,000 deaths (15.4% of all cancer deaths) in 2012, of 
these, 92,000 in the European Union alone. In developing countries breast cancer caused 
about 324,000 deaths (14.3% of all cancer deaths) in 2012. The mortality rates were ranging 
from 6 per 100,000 in Eastern Asia to 20 per 100,000 in Western Africa [1] (Figure 2). 
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Figure 2. Age-standardized mortality rates of breast cancer per 100,000 (adapted from 
GLOBOCAN 2012, IARC). 
In Sweden breast cancer accounts for almost 30% of all cancers and for 13.5% of all cancer 
deaths, with a risk of dying from the disease by the age of 75 years of 1.5%. About 8,000 
women develop breast cancer every year. The age-standardized incidence has almost doubled 
between 1960 and 2010 (Figure 3) while there has been a parallel decrease in mortality over 
calendar time. The incidence has been steadily increasing by 1.3% in the last 20 years, but 
this increase has been weaker (0.9%) in the last 10 years maybe due to the decrease in the use 
of hormone replacement therapy (HRT) or to saturation in mammographic screening. The 
current risk of developing breast cancer by the age of 75 years for Swedish women is 9.1%. 
The 5-year survival of a breast cancer patient is estimated to be around 92% [2]. 
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Figure 3. Age-standardized incidence and mortality rates of breast cancer per 100,000 in the 
Swedish female population (age 0-74 years) over calendar time (from NORDCAN 2014). 
Breast cancer survival has improved dramatically in the last few decades. The 5-year survival 
for a breast cancer patient went from less than 70-80% in the 1970s to about 90% in recent 
years with some differences according to age at diagnosis and tumor subtype [3, 4] (Figure 
4). This remarkable improvement is due to several factors, and in particular to adjuvant 
treatment (treatment given following surgery) and early diagnosis. Early diagnosis allowed 
more conservative treatment approaches, thus improving the quality of life of breast cancer 
patients. New polychemotherapy regimens have contributed to about 25% decrease in annual 
death rates from 1980s and, in combination with 5-year hormonal treatment, have 
approximately halved death rates among middle-aged women with estrogen receptor (ER)-
positive tumors [5]. 
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Figure 4. Secular trends in age-specific survival of Swedish breast cancer patients by 
calendar time and by age (from NORDCAN 2014). 
 
2.2 NATURAL HISTORY 
2.2.1 Risk factors 
2.2.1.1 Hereditary and genetic 
Breast cancer is a malignancy with an important hereditary component. A family history of 
breast cancer in a first-degree relative implies a two-fold life-time increased risk of 
developing breast cancer. If more than one first-degree relative have been diagnosed with 
breast cancer, the risk can be even higher. Two high penetrance susceptibility genes are 
known to be very strongly associated with breast cancer: BRCA-1 and BRCA-2 [6]. These 
genes are transmitted in a dominant fashion from parent to children and they carry a 45-65% 
life-time risk of developing the disease. About 16% of breast cancer is attributable to any of 
these two genes that are also responsible for an increased risk of ovarian cancer and other 
cancers also in males [7]. Other high penetrance genes have been more recently identified but 
they are considered rather rare: TP53, PTEN, STK11 and CDH1. Also quite rare are 
intermediate penetrance genes like CHEK2, ATM, BRIP1 and PALB2 [8]. Single gene 
inheritance is considered to contribute to about 20% of all familiar risk of breast cancer [7], 
all remaining cases are believed to have a polygenic component. This means that specific sets 
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of genes variants, that individually would only slightly increase the risk, can actually cause 
breast cancer. In order to identify such sets of genetic variants, genome-wide association 
(GWAS) studies are used in order to compare single nucleotide polymorphisms (SNPs) 
across different genes between breast cancer cases and controls. SNPs are variations across 
individuals at a single position in the DNA sequence that are studied for their possible 
association with specific phenotypes (e.g., risk of developing diseases, drug resistance, 
survival). The Breast Cancer Association Consortium has recently assessed 41 common non-
synonymous SNPs previously indicated by the Wellcome Trust Case Control Consortium 
(WTCCC) as associated with breast cancer [9]. Recent GWAS have identified up to 77 SNPs 
in breast cancer susceptibility loci [10] and some SNPs have also been reported to be 
associated with breast cancer prognosis [11]. The GWAS need to use large number of 
subjects in order to obtain enough power to detect signals and therefore are often performed 
by big consortia and require a lot of genetic data available. The GWAS approach only allows 
for generation of hypotheses as they are not aimed at testing a priori hypotheses [12]. 
2.2.1.2 Hormone-related 
Breast tissue is responsive to sex hormones, and to estrogen in particular. Sex hormones 
regulate the growth and the function of the breast gland, though only a minority of normal 
breast cells expresses receptors for estrogen (and progesterone) [13]. The overexpression of 
estrogen receptors, particularly in postmenopausal women, is associated with an increased 
risk of breast cancer [14]. Moreover, an association between risk of breast cancer and 
persistently high levels of blood estrogen has been found in many studies [15]. Most non-
hereditary breast cancer risk factors seem to be actually related to endocrine or exogenous 
estrogen exposure through different mechanisms [13]. 
The duration and estrogen-exposure variations in the reproductive life of a woman can 
modify the life-time risk of developing breast cancer. Young age at menarche and older age 
at menopause (i.e., longer reproductive life, more menstrual cycles and more exposure to 
cyclic sex hormones incretion by the ovaries) increase the risk of breast cancer [16, 17]. 
Breastfeeding, younger age at first full-term pregnancy and multiple full-term pregnancies 
independently decrease the risk of breast cancer [18, 19]. It seems in fact that the number of 
undifferentiated cells in the breast decreases at each pregnancy, thus lowering the long-term 
risk of potential malignant transformations [20]. Nevertheless, intrauterine life and pregnancy 
have also been discussed as possible moments when the exposure to sex hormones can 
increase the risk of developing breast cancer [20]. Also a high body mass index (BMI) may 
increase the risk of developing breast cancer in postmenopausal women [21]. The conversion 
of androgens to estrogens in the adipose tissue is actually the main source of endogenous 
estrogen exposure in postmenopausal women [22] and may be the reason of the increased risk 
in women with a high BMI. 
Exogenous hormone exposure is also associated with the development of breast cancer. In the 
1990s many women underwent hormone replacement therapy (HRT) in order to reduce the 
side effects of menopause (e.g., hot flashes, bone loss, hypertension). They were given HRT 
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either through estrogen alone or in a combination of progesterone and estrogen. After some 
years, an increased incidence of breast cancer was detected in these women suggesting a 
direct link with HRT and with postmenopausal exposure to sex hormones [23]. The risk 
increased with the duration of use and was estimated to be about 7.6% per year when using 
estrogen and progesterone in combination [24]. Oral contraceptives have also been found to 
be associated with an elevated risk of breast cancer in current or recent users [20]. 
2.2.1.3 Breast density 
Mammographic density is another risk factor for breast cancer and is thought to be associated 
with heritability and cumulative exposure to estrogens. It is not clear whether it is also a 
predictor of aggressiveness of the tumor since it does not seem to be associated with the risk 
of distant recurrence, with tumor characteristics, or with known molecular breast cancer 
subtypes [25, 26]. Some recent studies suggest that changes in breast density during 
hormonal treatment can serve as long-term predictors of prognosis [27]. 
2.2.1.4 Age 
As for most solid cancers, the risk of developing breast cancer increases with age. In 
particular there is a steep natural increase in the incidence of the disease at around the age of 
50 years independent of screening, suggesting an association with menopause and with the 
related change in hormone incretion. However, breast cancers that are developed at a younger 
age are usually more likely to be caused by genetic predisposition, to be more aggressive and 
to carry a worse prognosis.  
2.2.1.5 Other risk factors 
Studies carried out on atomic bomb survivors in Japan have shown a significantly increased 
risk of cancer even years after exposure to ionizing radiation. An apparent dose-response 
relationship with breast cancer was found among survivors. The risk of breast cancer was 
higher for exposures occurring at a younger age as compared with exposures occurring at an 
older age [28]. Alcohol intake was found to be associated with a moderate increase in risk of 
breast cancer in some studies [29]. A weekly moderate physical activity and an exposure to 
some vitamins in the diet have been reported to have some degree of protective effect but the 
studies are quite inconsistent [20, 30]. There is no current evidence that smoking is associated 
with the risk of breast cancer [31]. Finally, as for many other cancers, a previous diagnosis of 
breast cancer significantly increases the risk of other future primary breast cancers in the 
same person. 
2.2.2 Cancer growth and spread 
2.2.2.1 Carcinogenesis 
Carcinogenesis describes the process of cancer initiation and evolution through a multistep 
process. It is still a controversial topic and several theories have accumulated over the years. 
For the cancers not directly inherited through the germline of the carrier (the so-called 
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sporadic cancers) there are two main prevailing theories. The somatic mutation theory has 
been prevailing for the last 50 years and considers that cancer originates from a primary 
disruption of the cell cycle in a single cell (monoclonality). Basically a single normal cell 
undergoes a series of consecutive mutations of its DNA in genes that control cell proliferation 
and cell cycle. These events cause an uncontrolled and increasingly undifferentiated 
proliferation that will alter the normal tissue’s architecture and function, and will eventually 
lead to cancer growth, invasion and spread. During following subsequent mutations, cancer 
cells may acquire also the capacity to invade tissues and to undergo metastatic (i.e., distant) 
spread [32]. 
An alternative and more recent theory (the tissue organizational field theory) considers as the 
main driver of the carcinogenetic process an alteration of the microenvironment that controls 
the functional architecture of the normal tissue [33, 34]. The role of the microenvironment in 
the tumor development has been recently studied with increasing interest. It was found that 
stromal cells like fibroblasts, that are not parenchymal cells of a given organ from which a 
carcinoma usually originates (e.g., breast epithelial cells), are potentially able to modulate the 
carcinogenic process and to create the ideal conditions for cancer growth and spread [35]. 
2.2.2.2 Cancer invasion 
Cancer invasion is the process by which a carcinoma (i.e., cancer) develops the capacity to 
go beyond the basal membrane of an epithelium and invade the stroma (i.e., mesenchymal 
tissue) where most blood vessels and lymphatic vessels are located, therefore acquiring the 
potential for distant spread. This step is the first event in the so-called “metastatic cascade” 
and it involves an initial loss of the cell-to-cell adhesion thus enabling cells to detach from the 
primary tumor. These cells then need to acquire a motile phenotype through changes in the 
cell-matrix interaction in order to perform the actual stromal invasion. The interaction 
between the primary tumor and the stroma are also very important for the angiogenesis (i.e., 
generation of new blood vessels) that the tumor needs for its development when it exceeds a 
certain size (about 2mm) [36]. 
2.2.2.3 Distant spread 
Metastasis is the result of the spread of a cancer outside of the organ and of the tissue where it 
originated. It is a complex and still not completely understood process that can negatively 
impact the overall prognosis of a cancer patient.  
Distant spread classically can follow two main pathways: cancer cells can either migrate 
through the blood or they can spread via the lymphatic system and the lymph nodes. For 
distant metastasis to develop, cancer cells need first, to acquire the capacity to invade the 
surrounding connective tissue (i.e., stroma) and to enter the blood vessels or the lymphatic 
channels (intravasation); then, to be able to migrate and survive against mechanical strain and 
immune cells in the blood stream or in the lymph; and eventually, to exit the blood vessels or 
the lymphatic channels (extravasation). Finally, in order to grow a secondary tumor mass in 
the new tissue, the cancer cells need to be able to survive in the new microenvironment and to 
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create the conditions for their proliferation and growth by developing a suitable local vascular 
system (i.e., angiogenesis) [37-39]. 
Breast cancer metastatic dissemination commonly privileges an initial lymphatic spread to the 
loco-regional lymph nodes, more often of the ipsilateral axilla. Alternatively, depending on 
the location of the tumor, the loco-regional metastatic spread can initially affect the internal 
mammary nodes close to the sternum, or the infraclavicular and supraclavicular nodes, but 
these locations are much less frequent. The lymphatic spread to the loco-regional lymph 
nodes has many relevant implications in the management of breast cancer and may influence 
the decision to perform an axillary node dissection or even decisions concerning the adjuvant 
treatment to administer after the surgery.  
Distant metastasis can develop and grow in any organ and tissue of the body reaching its 
destination through the bloodstream (Figure 5). Each cancer, and specific subtypes of cancer 
as well, has preferential tissues where to spread. Breast cancer typically metastatizes to the 
skeleton, the liver, the central nervous system and the lungs: these are the organs and tissues 
were breast cancer metastasis tends to occur more often. Even metastatic cancer cells can 
show specific tissue tropism (i.e., predilection for specific organs/tissues) and the effect of the 
metastasis on the host tissue can be different according to the cancer of origin: bone 
metastasis in breast cancer patients tends to be preferentially osteolytic (i.e., with bone 
resorption capacity), while bone metastasis in prostate cancer for instance tends to be more 
often osteoblastic (i.e., with bone formation capacity) [36]. 
 
Figure 5. Metastatic spread of cancer through the blood vessels (from National Cancer 
Institute – NCI). 
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2.2.2.4 Recurrence 
After an initially successful treatment, cancer can relapse locally, regionally or directly with a 
distant metastatic presentation. All these events are called recurrences, and in the case of 
breast cancer they can take place either at the surgical scar on the breast, in the chest wall or 
in the remaining breast tissue (local recurrence); at the regional lymph nodes (regional 
recurrence); or in a distant organ (distant recurrence). Distance recurrences often convey a 
non-favorable prognosis and can only undergo a palliative treatment. Local and regional 
recurrences can instead be treated with a good success rate [40]. 
 
2.3 BREAST CANCER CLASSIFICATIONS 
Breast cancer can be classified according to different characteristics. The histopathological 
classification of breast tumors is the more traditional classification and is based on 
characteristics seen upon light microscopy of biopsy specimens. Current treatment, however, 
is mainly based on different aspects that relate to tumor aggressiveness, spread and molecular 
characteristics, therefore other classifications are also used. 
2.3.1 Histopathological classification 
The histopathological classification of invasive breast tumors identifies several types of 
breast carcinomas: ductal, lobular, mucinous (colloid), tubular, medullary, papillary, and 
other less common subtypes [41]. In addition to these, there are the mesenchymal tumors 
(including sarcomas) that do not originate from the breast tissue epithelium but from the 
connective and fat tissue surrounding the breast gland, and are rarer. The most frequent 
histological types of breast cancer are the ductal carcinoma and the lobular carcinoma that 
originate from the epithelium of the mammary ducts and lobules of the breast gland, 
respectively.  
The carcinoma in situ of the breast, as opposed to invasive breast cancer, is a malignant cells 
proliferation within the epithelium of the breast that is not crossing the basal membrane of the 
breast epithelium. The carcinoma in situ of the breast can be either a ductal carcinoma in situ 
(DCIS, much more common) or a lobular carcinoma in situ (LCIS), depending on the 
respective origin within the breast. With improved early breast cancer diagnosis the incidence 
of DCIS in particular is rapidly increasing, suggesting that many of these lesions might not 
actually evolve into an invasive tumor [42].  
2.3.2 Histologic grade 
Another classification of breast cancer takes into account the grade of the tumor, which 
defines the degree of aggressiveness and the potential for proliferation of the cancer cells 
within the tumor tissue. The grade of the tumor is assessed by a pathologist after a biopsy of 
the tumor tissue and is generally classified as low, when the tumor looks less aggressive, or 
as high, when the tumor looks more aggressive with an increased potential for fast 
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proliferation, invasiveness and spread. Different scoring systems for tumor grade have been 
proposed and applied for different cancers. The Elston-Ellis modification of the Scarff-
Bloom-Richardson grading system (Nottingham grading system) is the most often used for 
breast cancer. This grading system recognizes three levels, from low (grade I) to high (grade 
III) and the score is given based on three criteria: nuclear grade, tubule formation and mitotic 
rate [43]. 
The tumor grade strongly correlates with prognosis in breast cancer but it also strongly 
interacts with staging in predicting prognosis [44]. Some authors have argued that grade II 
(moderate) should not be taken into account in the assessment of indications for adjuvant 
therapy as it seems to be not as clearly correlated with prognosis as grade I and grade III [45]. 
Recent molecular profiling has identified protein signatures of histologic grading and 
suggested further subdividing grade II into two subcategories with significantly different 
prognostic value: grade IIa and grade IIb [46]. 
2.3.3 Biological/molecular classification 
A more recent and evolving classification of breast cancer subtypes, which is more directly 
linked to prognosis and current treatment, is the biological or molecular classification. It is 
based on the expression in the cancer cells of specific molecular receptors that can affect 
cancer growth pattern and behavior: the estrogen receptor (ER), the progesterone receptor 
(PR), the human epidermal growth factor receptor 2 (HER2/neu), and the cancer proliferation 
marker, Ki-67. These proteins are all modulators of cells growth and their level of expression 
can modify the prognosis of breast cancer. They can in fact predict the behavior of the disease 
and some can be also used as targets for treatment.  
2.3.3.1 Estrogen receptor status (ER status) 
The estrogen receptor (ER) is an intracellular protein that is coded by two different genes in 
two forms, α and β, and that binds to the sex hormone estrogen. The ER-α is mostly 
expressed in breast cells, endometrium, ovarian stromal cells and hypothalamus. The ER-β is 
notably more expressed in the bone, kidney, brain, heart, lungs, intestinal mucosa, prostate 
and endothelial cells. ER is overexpressed in about 70% of breast cancers and these will be 
called ER-positive cancers (thus possibly susceptible to hormonal treatment) (Figure 6). ER 
status at breast cancer diagnosis is a very important prognosticator since ER-negative and 
ER-positive tumors show rather different natural histories and are subject to different 
treatments [47, 48]. The ER expression and the ER status of the tumor found at breast cancer 
diagnosis can however change over time after neo-adjuvant or adjuvant treatment in about 
one third of cancers, and discordance in ER status may be found between the original tumor 
mass and the metastatic tissue. This may have important prognostic and clinical implications 
[49-51]. There has been a certain degree of heterogeneity in the past in the accuracy, 
precision and consistency of interpretation of the ER status (and also of PR status, HER2/neu 
status and Ki67 measurement) but the introduction of recent guidelines is trying to make the 
assessment more homogeneous [52, 53]. ER-negative breast cancers carry a significantly 
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poorer prognosis as compared to ER-positive breast cancers. The difference in survival can in 
fact last up to 11 years after diagnosis and is particularly pronounced in the first 5 years [5, 
54, 55]. 
 
Figure 6. Estrogen receptor staining in breast cancer tissue (from Itayba / CC BY-NC-SA 
3.0). 
2.3.3.2 Progesterone receptor status (PR status) 
The progesterone receptor (PR) is an intracellular protein that binds to the hormone 
progesterone and like the estrogen receptor it recognizes two forms, A and B. Although 
universally considered less important than ER status for breast cancer prognosis, there are 
some indications that low PR expression can possibly be associated with enhanced growth 
factor signaling and enhanced tumor aggressiveness [56]. PR status seems to also modify the 
responsiveness to specific hormone treatments [57, 58]. 
2.3.3.3 HER2/neu status 
The Human Epidermal Growth Factor Receptor 2 (HER2/neu) is a protein that is normally 
regulating cell growth, differentiation and survival. In 10-30% of breast cancers HER2 is 
overexpressed and this translates into an increased aggressiveness of the disease [59]. HER2-
positive status used also to imply a poorer prognosis until a new treatment, trastuzumab, was 
introduced in early 2000s. The introduction of trastuzumab dramatically improved the 
prognosis of HER2-positive breast cancer patients. The assessment of the HER2 status is 
considered of great clinical and prognostic relevance [60]. 
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2.3.3.4 Ki-67 proliferation index 
Ki-67 is a cellular protein that is strongly associated with cell proliferation. It is detectable in 
all active phases of the cell cycle (G1, S, G2, and mitosis) but it is absent in the resting phase 
(G0) [61]. The fraction of Ki-67 positive tumor cells is a reliable marker of cell proliferation 
and tumor growth and it is independently associated with survival. Ki-67 is routinely 
measured and used for prognosis and decision making in clinical practice. 
2.3.3.5 Biological/Molecular subtypes of breast cancer 
Despite the complexity of the genetic and molecular information that makes each breast 
cancer quite unique, the current molecular classification identifies four major subtypes that 
directly reflect into the disease behavior, prognosis and potential for treatment [62]: 
•   Luminal A (ER-positive and/or PR-positive, HER2-negative, with low Ki-67 expression): 
the most common molecular subtype of breast cancer accounting for about 40% of all 
invasive breast cancers; expected to be generally sensitive to hormonal treatment directed 
towards ER in particular; 
•   Luminal B (ER-positive and/or PR-positive, HER2-positive or HER2-negative with high 
Ki-67): the second most common molecular subtype of breast cancer; expected to be 
generally sensitive to hormonal therapy; usually of higher histological grade and worse 
prognosis as compared with luminal A; 
•   Triple negative/basal-like (ER-negative, PR-negative, HER2-negative): accounting for 
about 15-20% of all different subtypes and generally carrying the least favorable prognosis 
due to its aggressiveness and lack of receptors to be used as treatment targets [63]; 
•    HER2 type (ER-negative, PR-negative, HER2-positive): the least common subtype (10-
15%); currently treated with trastuzumab given its HER2 receptor positivity. 
Other subtypes have been identified in some studies (e.g., luminal C, normal breast-like) 
however they do not seem to be as strongly characterized [62]. Molecular classification of 
breast tumors is a complex, controversial and rapidly evolving subject. Molecular subtypes 
are currently mostly used only in research setting. In the clinical setting, many decisions are 
often taken based on the tumor grade, the tumor stage and the independent expression of ER, 
PR, HER2/neu and Ki-67. A full integration of the use of molecular breast cancer subtypes 
into the routine clinical setting could be beneficial. 
 
2.4 STAGING 
Staging is used in clinical medicine to define the extent of the spread of a cancer. The most 
frequent staging classification, which is commonly used also for breast cancer, is the TNM 
staging: each letter define a criteria that is given a specific score. The letter “T” stands for 
“tumor size” and is categorized as follows:  
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- TX = primary tumor cannot be assessed;  
- T0 = no evidence of primary tumor;  
- Tis = carcinoma in situ;  
- T1 = tumor size is less than 20mm;  
- T2 = tumor size is 20-50mm;  
- T3 = tumor size is larger than 50mm;  
- T4 = tumor of any size growing into the chest or skin.  
The letter “N” stands for “lymph node involvement” and is subdivided as follows: 
- NX = nearby lymph nodes cannot be assessed;  
- N0 = cancer has not spread to nearby lymph nodes;  
- N1 = cancer has spread to 1-3 axillary lymph nodes and/or tiny amounts of cancer can be 
found in internal mammary lymph nodes;  
- N2 = cancer has spread to 4-9 axillary lymph nodes or internal mammary lymph nodes 
are enlarged due to cancer;  
- N3 = cancer has spread to at least one axillary lymph node and has enlarged the internal 
mammary lymph nodes, or cancer has spread to four or more axillary lymph nodes and 
small amounts of cancer are found in internal mammary lymph nodes, or cancer has 
spread to supraclavicular lymph nodes with at least one area of the cancer spread greater 
than 2mm. 
The letter “M” stands for “distant metastasis”: 
- MX = distant spread cannot be assessed; 
- M0 = absence of distant metastasis on imaging procedures or on physical examination;  
- M1 = presence of distant metastasis.  
2.4.1 Tumor size 
The size of the tumor is a measure of local tumor growth and is taken by the pathologist 
measuring the largest diameter of the tumor mass [64]. Early diagnosis and the introduction 
of mass screening programs have contributed to the observed gradual decrease in tumor size 
found at breast cancer diagnosis. Women diagnosed with breast tumors smaller than 2 cm 
have more than 90% 5-years survival on average, while tumors larger than 5 cm at diagnosis 
have the worst risk of recurrence [65, 66]. Tumor size and number of positive axillary lymph 
nodes at breast cancer diagnosis are highly correlated but they may differently affect 
prognosis [67]. This might be due to the different propensity to metastatize of some 
molecular subtypes of breast tumor at different stages of the local tumor growth: the size of 
tumor at diagnosis does not in fact tell much about the growth rate of the tumor. Triple 
negative tumors for instance show an attenuated association between tumor size, lymph node 
status and survival [63]. 
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2.4.2 Lymph node status 
The presence and the number of metastatic (positive) loco-regional lymph nodes at breast 
cancer diagnosis is considered a very important prognostic marker in breast cancer patients 
and it is often taken into high consideration for the clinical decision making [67]. Lymph 
nodes status at breast cancer diagnosis is also an independent marker of tumor aggressiveness 
[68]. The number of affected lymph nodes is negatively associated with prognosis and the 
highest risk of recurrence is for patients who have four or more positive lymph nodes at 
diagnosis [69]. The axillary lymph nodes (Figure 7) are the most common site of loco-
regional metastasis and their surgical removal or irradiation is performed, when indicated, in 
order to avoid recurrences in the axilla, to assess prognosis and decide which type of 
additional treatment to perform. 
 
Figure 7. Anatomical disposition of lymph nodes in a normal breast ((from National Cancer 
Institute – NCI). 
2.4.3 Metastasis 
The presence of distant metastasis at breast cancer diagnosis is automatically considered 
stage IV, which is the stage with the worst prognosis according to the TNM staging system, 
and treatment is not considered curative. The development of distant metastasis is in fact still 
a predictor of negative prognosis in breast cancer patients (estimated 5-year survival: 22%), 
although a positive trend in survival has been observed in the last 15 years, at least in patients 
younger than 60 years at diagnosis [70]. Ongoing improvements in the understanding of the 
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metastatic process leading to a more targeted treatment will hopefully change the prognosis 
of metastatic patients in the next future. 
2.4.4 TNM stages 
The different stages of the TNM classification are derived based on the T, N and M scores.  
Stage 0 basically corresponds to ductal carcinoma in situ (DCIS) or non-invasive Paget 
disease of the nipple, while lobular carcinoma in situ (LCIS) is generally not considered a 
true cancer or pre-cancer.  
Stage I is defined by a tumor size less than 20mm with no macroscopic loco-regional or 
distant spread. Stage I is further subdivided into stage IA (T1 N0 M0) and stage IB (T0/T1 
N1mi M0, where N1mis indicates presence of micrometastasis in 1-3 axillary lymph nodes).  
Stage II is further classified as stage IIA and stage IIB: stage IIA can occur when the primary 
tumor is less than 20mm or undetectable in the concomitant presence of 1-3 positive axillary 
lymph nodes (T0 or T1, N1, but not N1mi, M0); or when the primary tumor is 20-50mm 
without any positive axillary lymph nodes distant spread (T2, N0, M0). Stage IIB occurs for 
instance when the primary tumor is 20-50mm and has 1-3 positive axillary lymph nodes (T2, 
N1, M0) or when it is larger than 50mm without any loco-regional or distant spread (T3, N0, 
M0).  
Stage III represents cancers that have spread loco-regionally but not to other organs. Stage III 
is categorized as stage IIIA (T0 to T2, N2, M0 or T3, N1 or N2, M0), stage IIIB (T4, N0 to 
N2, M0) and stage IIIC (any T, N3, M0).  
Stage IV corresponds to any cancer with distant spread to other organs independent of T and 
N scores (any T, any N, M=1) [64].  
TNM staging strongly correlates with prognosis and is widely used for clinical decision 
making [67]. Its integration with molecular subtyping can improve its capacity to predict 
prognosis and to more accurately indicate appropriate treatment [71], particularly in triple 
negative cancers [72]. 
 
2.5 TREATMENT 
2.5.1 Loco-regional treatment 
2.5.1.1 Surgery 
As for many other solid tumors, the treatment of breast cancer is primarily surgical. Until the 
1970s breast cancer was considered essentially a local disease, and surgery was practiced in a 
very extensive way through radical mastectomy that consisted in the removal of all breast 
together with all pectoral and chest muscles in contiguity with the breast, and of all the 
axillary lymph nodes draining from the breast. It was a very disfiguring type of surgery with 
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some remarkable side effects, like lymphedema of the upper limb due to the removal of all 
the lymphatic drainage from the arm [73].  
After the growing recognition of breast cancer as a systemic disease from the time of 
diagnosis, surgery started being considered a fundamental part of a more composite therapy, 
and not as the main treatment option. Different surgical procedures were gradually 
introduced: from the modified radical mastectomy (removal of the breast tissue and axillary 
lymph nodes, rarely performed nowadays) and the total mastectomy (removal of all breast 
tissue), to the breast conserving surgical approaches like quadrantectomies (removal of the 
affected quadrant of the breast) and lumpectomies (consisting in the removal of all the 
cancerous tissue and of some of the surrounding breast tissue). Breast conserving surgery was 
introduced because it showed similar effectiveness to more aggressive types of surgery when 
appropriately applied and followed by adjuvant treatment [74]. The idea behind breast 
conserving surgery comes from the lymph node sentinel approach: by injecting a dye into the 
breast close to the tumor during surgery, it is possible to see which lymph nodes are draining 
first from the cancer. These lymph nodes are then analysed for the presence of metastatic 
cells. If the lymph nodes are clear from cancerous cells, the tumor will be considered 
localized, and a breast conserving surgery will usually be carried out without any need of 
lymph node removal. If they are found to be affected, then an axillary lymph node removal 
will be considered as extensively as needed [75].  
Breast conserving surgery alone however is not enough to effectively prevent local and 
distant recurrence, and it has to be combined with additional treatment, usually given within 
weeks or months from surgery. This treatment aimed at reducing the chance of future 
recurrences is called adjuvant treatment and can be administered through different 
combinations of radiation therapy, chemotherapy, hormone therapy, and other types of 
targeted therapy. The decision on which combination of adjuvant treatment to use is based on 
several factors, including tumor staging, molecular characteristics of the tumor, histological 
grading, general conditions of the patient (e.g., age, comorbidities) and preferences of the 
patient [76]. 
2.5.1.2 Radiation therapy 
Radiation therapy after breast conserving surgery usually consists of an external beam 
irradiation of the remaining breast tissue, and of the surrounding area where surgery was 
performed, in order to reduce the chance of local recurrence if some cancerous tissue or cells 
were still left. Adjuvant radiation therapy has been shown to improve disease-free survival 
and breast cancer-specific survival. However, there have been some concerns about 
irradiation of the heart and possible consequent cardiovascular events, and also about 
irradiation of the lungs and increased long-term risk of second primary lung cancer [40, 77-
79]. Other possible side effects of radiotherapy for breast cancer include redness of the 
irradiated skin, lymphedema of the arm in case of irradiation of the axilla, and pneumonitis. 
New radiation therapy techniques, such as intensity modulated radiotherapy (IMRT), tend to 
employ smaller fields compared to the past [80] and this may mean fewer acute adverse 
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effects, however this may also mean more scattered doses to the lung and to other organs. 
International guidelines made specific recommendations balancing risk and benefit of the 
breast irradiation treatment. In Sweden the treatment is usually given in a total dose of 50 
Grays (Gy) with a daily dose of 2Gy for 5 days per week [81].  
2.5.2 Systemic treatment 
2.5.2.1 Chemotherapy 
Chemotherapy is a systemic treatment often given after surgery with the aim of eliminating 
remaining cancerous cells from the body. Chemotherapy usually tends to interfere with rapid 
cell proliferation and therefore is not only acting on cancer cells but also on normal cells. 
This means that chemotherapy is associated with a certain amount of toxicity according to the 
agent and the dosage used. Some of the possible adverse effects of chemotherapy during 
treatment are neutropenia (infections), anemia, bleeding, hair loss, nausea and vomiting, 
fatigue, diarrhea, constipation, sexual and fertility changes, skin and nail changes, swelling, 
urination changes, pain, and nerve changes [82]. Several types of chemotherapeutic agents 
can be used and they are usually combined in different polychemotherapeutic regimens: 
- cyclophosphamide, doxorubicin/Adriamycin, and 5-Fluorouracil; 
- docetaxel/Taxotere, doxorubicin/Adriamycin, and cyclophosphamide; 
- doxorubicin/Adriamycin and cyclophosphamide followed by paclitaxel/Taxol or 
docetaxel/Taxotere; 
- 5-Fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel/Taxotere or 
paclitaxel/Taxol; 
- docetaxel/Taxotere and cyclophosphamide; 
- docetaxel/Taxotere, carboplatin, and trastuzumab/Herceptin for HER2/neu positive 
tumors; 
- cyclophosphamide/Cytoxan®, methotrexate, and 5-fluorouracil (CMF); 
- doxorubicin/Adriamycin followed by CMF; 
- epirubicin/Ellence and cyclophosphamide; 
- doxorubicin/Adriamycin and cyclophosphamide. 
In Sweden, lymph node negative patients requiring chemotherapy are offered an 
anthracycline combination of drugs or CMF, while lymph node positive patients are 
recommended a stronger treatment with polychemotherapy involving anthracyclines and 
taxanes [81]. Chemotherapy is generally indicated for the treatment of triple negative breast 
cancers and is also commonly given in HER2-positive tumors in combination with 
trastuzumab. ER-positive, HER2-negative patients are offered chemotherapy if the tumor size 
is larger than 5cm, if there are four or more positive lymph nodes, if the histological grade is 
3, if there is a high proliferation rate, or if there is an extensive peritumoral vascular invasion 
[83]. However, some specific indications and therapeutic regimen choices may vary. 
Chemotherapy can also be given before surgery (neoadjuvant treatment), alone or in 
combination with other treatments (e.g., hormonal treatment). The aim of neoadjuvant 
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treatment is to reduce the mass of the primary tumor and the tumor loco-regional spread in 
order to enable or facilitate surgery and to increase chances of surgical success [84].  
2.5.2.2 Endocrine therapy 
Endocrine or hormone therapy is administered according to the molecular characteristics of 
the breast tumor. The selective estrogen receptor modulators (SERMS) can act as estrogen 
agonists or antagonists in different tissues and are the first and most common class of 
hormone treatment that has been utilized. Tamoxifen is the most widely used SERMS for 
breast cancer adjuvant treatment and is given to patients with tumors expressing the estrogen 
receptor (ER-positive). Tamoxifen is usually given for five years since breast cancer 
diagnosis in ER-positive patients [85-87], however new international guidelines suggest a 
prolonged use possibly up to ten years [88]. Unfortunately some relevant adverse effects 
might undermine its use for long periods: tamoxifen is in fact associated with an increased 
risk of vaginal bleeding, uterine malignancies, venous thrombosis, pulmonary embolism, hot 
flashes and night sweats [89-91]. The use of tamoxifen in small doses for the prevention of 
breast cancer has also been suggested [92]. 
Aromatase inhibitors are another class of hormonal treatment that has been introduced in the 
late 1990s. This class of drugs is able to interfere with the peripheral formation of estradiol 
(i.e., estrogen) by inhibiting the aromatase enzyme in the fatty tissue. Aromatase inhibitors do 
not affect the ovary incretion of estrogen, therefore they are effective in decreasing the level 
of circulating estrogen only in postmenopausal women, when the ovary has already ceased its 
activity. Aromatase inhibitors were shown to improve the disease-free survival but not the 
overall survival of breast cancer patients, probably due to some of their side effects on the 
heart and on the bone [5, 89-91, 93]. Aromatase inhibitors have been so far mainly 
recommended after 2-3 years of tamoxifen in postmenopausal breast cancer patients, so that 
hormonal adjuvant treatment can be performed without significantly increasing the risk of 
uterine cancer or of the other side effects related to the use of tamoxifen [5, 88-91, 93-96]. 
New guidelines are now recommending a prolonged use of hormonal treatment up to ten 
years since breast cancer diagnosis with different serial combinatins of tamixifen and 
aromatase inhibitors [88].  
2.5.2.3 Targeted therapies other than hormonal therapy 
New molecules within cancer cells and on cancer cells surface are being identified and can be 
potentially used as targets for new specific drugs. Just like hormone therapy, these targeted 
drugs do not affect the healthy tissue and specifically affect the tumor. The most famous non-
hormonal targeted therapy in breast cancer, that has successfully been in use for quite some 
years now, is the already mentioned trastuzumab, a monoclonal antibody acting against the 
HER2/neu through an antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism 
and therefore effective on HER2/neu overexpressing tumors (Figure 8). It is administered to 
HER2-positive patients following chemotherapy and has dramatically improved the 
prognosis of these patients [81]. Other similar drugs have been recently approved (e.g., 
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lapatinib, pertuzumab) and others are currently under development and hopefully in the future 
there will be more therapies allowing for instance the targeted treatment of triple negative 
breast tumors. 
 
Figure 8. Antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism of attack of 
breast cancer cells by the immune system (from Simon Caulton / CC BY-NC-SA 3.0).  
Some alternative types of targeted cancer treatment other than hormonal treatment and 
immunotherapies are apoptosis inducers, angiogenesis inhibitors, gene expression 
modulators, signal transduction inhibitors and monoclonal antibodies delivering toxic 
molecules [97]. 
 
2.6 CLINICAL FOLLOW-UP 
After the end of the treatment period regular medical examinations of breast cancer patients 
are periodically performed in order to detect possible recurrences at an early stage. The 
American Society of Clinical Oncology (ASCO) currently recommends performing a 
physical examination every three to six months for the first three years, then every six to 
twelve months until five years from diagnosis, and annually thereafter. Mammographic 
examinations should instead be performed annually. Other examinations are not 
recommended for routine follow-up [98]. 
 
2.7 HEALTH OUTCOMES 
2.7.1 Causes of death and disease-free survival 
Despite the aforementioned improvements, the survival of breast cancer patients is still lower 
than the one of the general population from the same age groups up to twenty years since 
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diagnosis [99, 100]. The risk of dying from breast cancer decreases with time since diagnosis 
and is usually higher in younger patients than in older patients. Conversely, the risk of dying 
from cardiovascular disorders and other cancers increases with age and consequently with 
time since breast cancer diagnosis [101, 102]. The impact of causes of death other than breast 
cancer is a topic of interest when looking at long-term outcomes in these patients. Moreover, 
few studies have tried to comprehensively take into account time trends, age, tumor 
characteristics, and treatment when studying the risk of dying from breast cancer [103, 104]: 
in particular, time-dependent variations by age at diagnosis and tumor characteristics of the 
survival patterns have not been thoroughly investigated.  
Understanding in detail the disease-free survival patterns of patients with different breast 
cancer subtypes is also of great clinical relevance. The development of distant metastasis still 
unfortunately means that the patient is beyond cure [40, 105, 106]. We know that triple 
negative cancers tend to metastatize earlier and more frequently than other breast cancer 
molecular subtypes, however this different behavior seems to disappear after five years since 
diagnosis among the survivors [107, 108]. The risk of developing distant metastasis may in 
fact vary over time since diagnosis and across different subgroups of patients [63, 109-111]. 
Its thorough understanding would enable to consider a more tailored clinical follow-up of 
breast cancer patients in the future. The prognosis after the development of distant metastasis 
has already been analyzed and studied in more detail. Following the development of distant 
metastasis, age at breast cancer diagnosis, hormonal receptor status and site of metastasis are 
the most relevant factors for predicting survival [70, 112, 113]. 
Women with a previous breast cancer diagnosis may also be more exposed to other health-
related conditions that can possibly affect their quality of life and their overall prognosis 
[114, 115]. This is an evolving area of relatively recent research thanks to the remarkable 
improvements in breast cancer survival. It is currently not quite clear what is the actual long-
term risk of developing comorbidities in breast cancer patients since most of the adverse 
events have been studied close to the administration of the treatment. Some recent studies 
have shown that comorbities like diabetes and stroke are significantly associated with the 
management and the survival of women with breast cancer [116, 117]. 
2.7.2 Bone fractures 
Some evidence of an overall increased risk of bone fractures in women diagnosed with breast 
cancer as compared with the general female population has already been found, however the 
determinants and the magnitude have not been completely clarified [118]. Bone cells can 
express estrogen receptors and bone tissue is quite sensitive to variations in estrogen levels. 
Due to the drop in estrogen levels after menopause, postmenopausal women are in fact at 
increased risk of osteoporosis and bone fractures, namely hip fractures (Figure 9), vertebral 
fractures and fractures of the wrist [119]. Hormone treatment can therefore also affect 
calcium and bone metabolism through different mechanisms and thus influence the risk of 
bone fractures [120]. For instance, aromatase inhibitors, through their peripheral antagonist 
action in postmenopausal women against estrogen formation, can directly induce bone loss 
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and cause bone fractures [121]. Tamoxifen has instead a protective effect on the bone thanks 
to its estrogen-modulator characteristics that make it act as an estrogen antagonist in the 
breast tissue and as an estrogen agonist in the bone tissue [85-87, 89, 122, 123]. Other types 
of oncologic adjuvant treatment can have a negative effect on the skeleton independent of sex 
hormonal metabolism [124, 125]. Increasing evidence suggests an involvement of the bone 
marrow microenvironment in the metastatic process, and a possible effect of bone-targeted 
drugs in reducing bone metastasis and improving survival [126, 127]. For all these reasons 
other drugs like bisphosphonates are currently administered in parallel to the aromatase 
inhibitors in order to reduce the risk of bone metastasis and to strengthen the bone tissue 
[128, 129]. 
 
Figure 9. X-ray of a hip fracture (from © Nevit Dilmen / CC BY-NC-SA 3.0). 
2.7.3 Infections 
Infections are known complications that can be observed in cancer patients and may due to 
cancer treatment, through immunosuppression, or to the cancer itself [130, 131]. Previous 
clinical trials have shown typical side effects of breast cancer treatment. For instance, it is 
well known that most chemotherapy agents and regimens can cause a decrease in blood cell 
counts, in particular neutrophils, thus leading to an increased risk of infections during the 
treatment period. Radiation therapy is administered locally and can cause some skin 
inflammation that sometimes can be subject to infection. Surgery itself, particularly when 
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removal of axillary lymph nodes is involved, can possibly lead to an increased risk of 
lymphedema of the upper limb with potential swelling and movement impairment, and also 
to subsequent skin infections (Figure 10). 
 
Figure 10. Skin infection (erysipela) of the upper limb (from Poupou l'quourouce / CC BY-
NC-SA 3.0). 
Cancer patients with infections can experience prolonged hospitalizations and treatment delay 
[132, 133] as well as a worse long-term prognosis [130, 134]. Research has so far mainly 
focused on infections associated with neutropenia during periods of adjuvant treatment [134, 
135] and little is known about the incidence of infections in breast cancer patients beyond the 
treatment period. Specific tumor characteristics and adjuvant therapies may predispose to 
certain types of infections even following the end of the treatment, but not much information 
is currently available on this topic.  
2.7.4 Other potential health outcomes 
There is also evidence that women with breast cancer may be at increased risk of other 
health-related conditions. These additional health outcomes should be taken into account as 
well in the management of breast cancer patients. 
2.7.4.1 Second primary cancers 
It is well-known that women with a breast cancer diagnosis are at significantly increased risk 
of developing other primary cancers as compared to women without a history of breast 
cancer. BRCA-1 gene carriers have for instance a cumulative risk of developing a 
contralateral breast cancer of 87% by the age of 70 years and a risk of 44% of developing 
ovarian cancer by that time; they are also at 4-fold increased risk of developing a primary 
colon cancer [136]. Also, in all breast cancer patients increased percentage risks were found 
for the following cancers: soft tissue sarcoma (125%), thyroid cancer (62%), non-melanoma 
skin cancer (58%), leukemia (52%), endometrial cancer (52%), stomach cancer (35%), 
melanoma (29%), kidney cancer (27%), lung cancer (24%), colon cancer (22%) [137]. 
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Moreover, as already discussed, the prolonged used of tamoxifen contributes to the increased 
risk of uterine cancer in breast cancer patients [90] and the exposure to irradiation may 
increase the long-term risk of second primary lung cancer [78] in particular among cigarette 
smokers [77]. 
2.7.4.2 Endocrine disorders 
An association between diabetes mellitus and cancer has been found by several studies [138, 
139]; there may be several reasons for this association but the real causes are currently not 
very well understood [140]. Diabetes mellitus however seems to be more of a risk factor for 
breast cancer and subsequent death [141-143].  
2.7.4.3 Circulatory system disorders 
Women with a previous breast cancer diagnosis can also be at increased risk of circulatory 
system disorders. Exposure to radiation therapy to the breast can affect the heart and may 
cause an increased risk of myocardial infarction from few years after irradiation up to at least 
20 years since breast cancer diagnosis, particularly in women at previously increased risk of 
ischemic heart disease [79]. Other adjuvant treatment, like for instance anthracyclines agents 
used in chemotherapy and aromatase inhibitors, were found to have some toxic effect on the 
heart [89, 144].  
Venous thromboembolism (VTE) is a common known complication of malignant diseases 
but its pathophysiology still remains poorly understood. VTE can also cause pulmonary 
embolism. The risk of deep vein thrombosis has been found higher in patients undergoing 
surgery for a malignancy, and the risk of recurrence after a first episode of VTE is higher in 
cancer patients than in other patients [145-147]. Additionally, patients with cancer who 
developed a VTE have a lower survival compared to cancer patients who did not develop a 
VTE [148]. As already mentioned, women treated with tamoxifen face an increased risk of 
blood clots and pulmonary embolism.  
2.7.4.4 Neurological disorders 
Recent studies have also highlighted a significant association between Parkinson’s disease 
and breast cancer. Parkinson’s disease is usually associated with a decreased overall risk of 
cancer, with breast cancer and skin cancers as notable exceptions. The mechanism of this 
association are not clear, however common risk factors including, but not exclusively, genetic 
predisposition are considered among the most likely culprits [149-153].  
Chemotherapy has been also suspected to cause frontal dementia, the so-called “chemo-
brain”, and other neurological disorders in breast cancer patients, however little evidence 
emerged from previous studies on this matter [154].  
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2.7.4.5 Psychiatric disorders 
Lastly, breast cancer can take an important psychological toll that can often go under-
recognized or undertreated. Although major depression does not seem to occur in the 
majority of breast cancer cases, women with a previous breast cancer diagnosis have shown 
an increased risk for this condition. Breast cancer patients can also experience treatment-
related distress, post-traumatic stress disorder, other mood disorders, functional impairments, 
fear of recurrences, changes in body image and in sexuality in up to one third of cases, and 
some of these symptoms may last up to twenty years since breast cancer diagnosis [155-157]. 
Taking care of the psychological side effects of a breast cancer diagnosis and of the related 
treatment should be considered part of the routine clinical management of breast cancer [158, 
159].
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3 AIMS OF THE THESIS 
The aim of this thesis was to investigate and describe the medium- and long-term health 
outcomes of women with breast cancer over time since diagnosis by looking at causes of 
death, first distant metastasis and causes of hospitalization, and to study potential 
associations with age at diagnosis, tumor characteristics and treatment.  
In order to reach these goals, four studies on women with a diagnosis of invasive breast 
cancer in Sweden were performed using population-based registries: 
 
Study I: to investigate causes of death and time-dependent effects of age and tumor 
characteristics on risk of dying from breast cancer; 
 
Study II: to investigate the sites of first distant metastasis and the time-dependent effects of 
age and tumor characteristics on risk of developing distant metastasis; 
 
Study III: to investigate the risk of hospitalization due to bone fracture in women with 
breast cancer; 
 
Study IV: to investigate the risk of hospitalization due to infection in women with breast 
cancer. 
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4 MATERIALS AND METHODS 
4.1 DATA SOURCES 
Data were collected through Swedish population registers. In Sweden a unique identification 
number (ID) is available for all citizens [160]. The Swedish id number is a 10-digit numerical 
identifier that has been in use in Sweden since the 1940s. The first six digits refer to the date 
of birth, the following two used to refer to the place of birth, the second last digit refers to the 
gender and the last digit is a control digit that is calculated based on the other nine digits, so 
that it would give an error message in case of mistakes in entering the previous nine digits.  
4.1.1 Swedish population register 
It comprises information on demographic individual data of all Swedish citizens (e.g., unique 
ID, name, date of birth, place of birth, civil status, address) that can be linked through the 
unique ID to the other population registers [161]. Demographic information about the 
Swedish population can be traced back since the 17th century and was initially collected by 
the Church before becoming a population register. 
4.1.2 Swedish cancer register 
Established in 1958, the Swedish National Cancer Register (NCR) contains information on 
all primary incident cancers diagnosed in Sweden [162]. Given the mandatory independent 
reporting of physicians and pathologists, the register has reached a high level of accuracy and 
99% completeness [163]. All cancers are classified according to the International 
Classification of Diseases (ICD) and 99% have also been morphologically verified [164, 
165]. 
4.1.3 Stockholm-Gotland breast cancer register 
The Stockholm-Gotland breast cancer register (SBCR) registered all primary breast cancer 
cases in the counties of Stockholm and Gotland since 1976 and has 99% completeness for 
women less than 75 years at diagnosis. The register contains detailed information about 
breast cancer tumor characteristics and treatment and is also used to verify the quality and 
equity of breast cancer care across different healthcare centers [166]. 
4.1.4 Cause of death register 
All causes of death are mandatorily reported and the computerized version of the register is in 
place since 1952. Information is considered reliable since 1961, with basically no missing 
death, and is reported according to the ICD as underlying cause of death with up to 10 
contributing causes of death. In particular, it is able to correctly classify up to 98% of breast 
cancer deaths [167, 168]. 
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4.1.5 Inpatients register 
The Swedish National Inpatient Register includes information about all hospitalizations 
occurring in Sweden and reports data on the main cause of hospitalization. It was established 
in the 1960s and since 1987 it includes all information about inpatient care in the whole of 
Sweden. The information available in the national register is divided into patient data, 
geographical data, administrative data and medical data and is updated once a year. Quality 
control is routinely carried out and the drop-out rate was estimated to be less than one per 
cent in 2007 [169, 170].  
 
4.2 STUDY POPULATIONS 
4.2.1 The Stockholm-Gotland regional cohort 
In studies I-III, we used a study population of Swedish breast cancer patients diagnosed in the 
period between 1 January 1990 and 31 December 2006 in the Stockholm and Gotland 
counties. Women with a first diagnosis of breast cancer, younger than 75 years and with no 
previous cancer diagnosis, were extracted from the SBCR. In all three studies some additional 
exclusions were made:  
- women who did not undergo any surgery: these women do not have pathologic 
information available from surgery and might not be operated for their breast cancer 
due to some specific reason unrelated to the disease; 
- women who underwent neoadjvant treatment: the pathologic information available 
may have been affected by the treatment carried out before surgery;  
- women with a stage IV breast cancer: these patients would undergo palliative 
treatment; 
- women who had a reported tumor size less than 1mm: reporting a size less than 1mm 
for an invasive cancer may significantly increase the chance of considering a 
carcinoma in situ, or even a non-malignant lesion, an invasive breast cancer. 
After all exclusions, in study I and study III the cohort comprised 12,850 women with a 
previous breast cancer diagnosis (Figure 11). In study II (N=12,322) women diagnosed with 
distant metastasis within the first three months since breast cancer diagnosis and women with 
breast cancer as underlying cause of death but no distant metastasis reported in the SBCR 
were also excluded from the analysis.   
Information on date of breast cancer diagnosis and treatment was complete for all women. 
Information on number of positive lymph nodes and tumor size was available for 94.6% and 
98.4% of women, respectively, while information on ER status was available for 80.3%.   
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CDR: Cause of Death Register 
SBCR: Stockholm-Gotland Breast Cancer Register 
Figure 11. Flowchart of the Stockholm-Gotland regional cohort (Study I). 
In studies I-III, this cohort of breast cancer patients was followed until event occurrence, 
censoring date, or 31 December 2006 (end of follow-up), for maximum 10 years since 
diagnosis. 
4.2.2 The Swedish national cohort 
In studies III and IV, part of the analysis was performed on a national cohort of breast cancer 
patients selected from the NCR, and linked to the Total Population Register, the CDR and the 
Inpatients Register. This Swedish nationwide cohort of women diagnosed with breast cancer 
between 1 January 1990 and 31 December 2009 (end of follow-up) included 77,174 
individuals. Breast cancer patients were followed for hospitalization or death from bone 
fractures and infections and were then compared with the rates of hospitalization due to bone 
fracture and infection in the general Swedish population. 
CDR 
N=13,307 
SBCR cohort 
N=32,153 
Merge 
SBCR-CDR 
Main analysis dataset 
N=12,850 
Stockholm-Gotland,1990-2006 
N = 16,944 observations excluded 
1) Non-invasive cancer:  n=2,260 
2) Diagnosed <1990: n=10,248 
3) Previous cancer:  n=2,296 
4) Neo-adjuvant treatment:  n=1,103 
5) Tumor size < 1mm:  n=1 
6) No surgery: n=1,020 
7) Stage IV tumors:  n=16 
8) Age >74 yrs: n=2,345
   
N=14 women excluded with no 
match in the NCR 
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4.2.3 The LIBRO-1 cohort 
The Linné-bröst 1 (LIBRO-1) cohort is a regional cohort of 9,328 women diagnosed with 
primary invasive breast cancer in the period 2001-2008 in the Swedish counties of Stockholm 
and Gotland. The cohort is linked to the Information Network for Cancer care (INCA) 
register of all Swedish quality registers [171] and to the Regional Cancer Centers (RCC) 
[172]. INCA was initiated in 2007 and includes records of all women diagnosed with breast 
cancer in Sweden. It contains detailed information about tumor characteristics (e.g., 
histological grade, tumor size, estrogen receptor status, number of positive lymph nodes) and 
treatment, including type of surgery performed. 
In study IV, the LIBRO-1 cohort was used in order to investigate the risk of being 
hospitalized with an infection over time since breast cancer diagnosis according to age, tumor 
characteristics and treatment. After applying the same exclusion criteria as in the Stockholm-
Gotland regional cohort (see 4.2.1), 8,111 breast cancer patients were included in the 
analysis. 
4.2.4 The CAHRES study 
In study IV, a sensitivity analysis of the main findings from the LIBRO-1 cohort was 
performed using a population-based case-control study on postmenopausal women, the 
Cancer And HorMonEs in Sweden (CAHRES) study, to assess potential unmeasured 
confounding. The CAHRES study comprises women aged 50-74 years with no previous 
breast cancer diagnosis, resident in Sweden between 1 October 1993 and 31 March 1995 
[173]. Cases were identified from the six Swedish regional cancer registers where 98% of all 
cancer diagnoses in Sweden are reported, and controls were randomly chosen from the Total 
Population Register. In total, 2,802 breast cancer cases and 3,113 population-based age-
matched controls were included. All cases and controls had detailed information on 
background risk factors (i.e., body mass index, lifestyle factors and disease history) and had 
complete follow-up till death, emigration and inpatient hospitalizations or until 31 December 
2008 [174]. 
 
4.3 STATISTICAL ANALYSIS 
4.3.1 About survival analysis 
Survival analysis comprises all the methodologies studying the effect of an exposure on time 
to an event occurrence, such as death, hospitalization or disease recurrence. It focuses on time 
to event data and enables the study of the likelihood of a certain event at a certain time point, 
given that the subject (observation) has “survived” till that time point [175]. In our studies we 
used survival analysis in order to investigate the risk of developing different types of 
outcomes over time since diagnosis in breast cancer patients.  
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In survival analysis the dependent variable generally has two dimensions: the event indicator 
(usually a binary indicator) and the time at risk, and it can therefore be considered a rate in 
mathematical terms. The hazard (or event rate) can be also seen as the “speed” (rate) of 
events occurring over time.  
Survival analysis is based on a density function f(t), on a survivor function S(t) and on a 
hazard function h(t). The density function f(t) corresponds to the probability distribution of 
failure times in a subject, the F(t) denotes the cumulative probability distribution of failure 
times or failure proportion (cumulative density function), while the survivor function is the 
probability of surviving (i.e., not failing) at least until time t: S(t)=Pr(T≥t) (Figure 12). The 
relationship between the survivor function and the cumulative density function is the 
following: S(t)=1-F(t). 
 
Figure 12. Example of a survival curve of breast cancer patients (event=death) by lymph 
node status. 
The rate in decline of the survival proportion (i.e., the proportion of “alive” subjects at time t 
over the total number of subjects “alive” at time zero) is instead called hazard function. The 
hazard function is defined as the instantaneous event rate (i.e., hazard) at time t conditional on 
survival till time t. The hazard function can alternatively be presented as cumulative hazard 
function, conventionally denoted as ᴧ(t). The formula linking the survivor function to the 
cumulative hazard function is the following: S(t)=exp(-ᴧ(t)) 
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4.3.1.1 Estimators commonly used in survival analysis 
The survivor and the hazard functions can be estimated through specific parametric 
distributions based on certain density functions. Some of the most commonly used parametric 
survival distributions in medical survival studies are the exponential distribution, the Weibull 
distribution, the Gompertz distribution and the log-normal/log-logistic distribution [176]. If 
parametric distributions are appropriate, they will result in more efficient estimates (i.e., 
narrower confidence intervals) of the parameters of interest. Unfortunately the assumption of 
an inappropriate distribution for survival time will result in wrong estimates. 
An empirical estimate of the survival function may also be developed using non-parametric 
estimators. Non-parametric methods for estimating the survivor function involve estimating 
the survival proportion at discrete values of time t and then interpolating them. The most 
common non-parametric estimation of the survival function is the Kaplan-Meier method 
which is defined as the probability of surviving in a given length of time while considering 
time in many small intervals. Starting with the shortest survival time the interval of time is 
tabulated in ascending order for which probabilities of occurrence of event are evaluated; and 
these successive probabilities are multiplied by any earlier computed probabilities to get the 
final estimate. The Kaplan-Meier estimator is also called “product limit estimate”. 
The Kaplan Meier estimator is quite similar to life tables (actuarial estimator), another 
common non-parametric method for the estimation of the survival function. The non-
parametric estimators are often used since they are fairly robust, efficient as compared to 
parametric tests, and rather easier and intuitive to understand. 
4.3.1.2 Testing differences in survival 
Median survival can be used as a measure to summarize and compare the survivals in 
different cohorts or subgroups and it represents the time t at which the survivor function S(t) 
falls below 0.5 (50%). The cumulative survival can be used as well for this purpose and it 
simply consists in the proportion of subjects still “alive” at a certain time t (i.e., 5-year 
survival in cancer epidemiology). There are several parametric and non-parametric methods 
to statistically test the differences between survival curves in different groups. The most 
commonly used is the non-parametric log-rank test. The log-rank test can be roughly 
compared to a chi-square test incorporating follow-up time and is typically used to test the 
difference of univariate Kaplan-Meier survival curves across different subgroups of patients. 
Kaplan-Meier curves are also widely used even for simple graphical comparisons (Figure 
12). However, it is always preferable whenever possible to use modelling because it also 
allows the study of confounding and effect modification, and because it provides with 
estimations (e.g., hazard ratios) rather than just visual comparisons or testing of a null 
hypothesis. 
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4.3.1.3 Proportional hazards and time-dependent effects 
Some of the most common models used in survival analysis (e.g., Cox regression) assume 
proportional hazards over time across different levels of exposures. The proportional hazards 
assumption in fact implies that the survival curves within two strata are proportional over 
time (i.e., the hazard ratio does not vary over time). In real life, the hazard ratio comparing 
specific covariate patterns can actually vary over time. When appropriate, it may be thus 
more correct to allow for time-dependent effects in the models in order to be able to study 
time-varying hazard ratios. This is particularly useful as follow-up time gets longer and as the 
effect of a covariate on the event of interest can be modified by follow-up time, as when 
studying long-term effects of an exposure. 
4.3.1.4 Statistical models used in survival analysis 
Hazard functions in survival analysis can be modelled in different ways by using non-
parametric, semi-parametric and parametric models. Parametric models typically assume a 
known underlying distribution of the parameters considered, as for instance a Weibull or a 
lognormal distribution. However it is sometimes difficult to assume the underlying 
distribution of such parameters and an inaccurate assumption may lead to misleading results. 
Some parametric distributions like the Weibull are often criticized as they assume a 
monotonic increase or decrease of the baseline function that do not allow for more complex 
patterns. The use of mathematical piecewise polynomials, also known as splines, allows 
instead for more flexibility and complexity. The points at which each polynomial joins are 
called knots. In our studies we used in particular three types of survival models: the Cox 
regression model, the Poisson regression model and the flexible survival models. 
4.3.1.4.1 Cox regression model 
The Cox regression model is a widely used semi-parametric model that allows for 
comparison of effects of different exposures on a time to event outcome [177]. The model 
links the hazard for an individual subject at time t (i.e., λ(t)) to the baseline hazard λ0(t) by the 
following equation:  ln[𝜆(𝑡|𝑋)] = 𝑙𝑙[𝜆0(𝑡)] + 𝛽𝑋 
The Cox regression does not make assumptions about the baseline hazard function, thus 
considered semi-parametric, and it assumes non-informative censoring (see 4.3.1.5).  The 
Cox regression model can be adjusted for different covariates and it usually assumes 
proportional hazards, so that hazard ratios are expected to be constant over time (i.e., not 
time-dependent). In other words, this means that the hazards of each exposure level are 
assumed to be parallel over time on the log scale. The Cox regression model allows for 
comparison across different levels of exposures by estimating hazard ratios (HR). The 
proportional hazards assumption is a strong assumption and should always be tested. We used 
Cox regression in study III and study IV when studying the association of age and tumor 
characteristics with risk of hospitalization among breast cancer patients. 
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4.3.1.4.2 Poisson regression model 
Poisson regression belongs to the family of generalized linear models and allows modelling 
of event rates. It assumes that the logarithm of the event rate variable is linearly related to the 
exposure variable (log-linear regression) according to the following formula: 
𝑙𝑙(𝜆) = 𝛽0 + 𝛽1𝑋 
The parameter β1 is the effect per unit increase of X as a change in the log rate. Poisson 
regression model estimates the baseline hazard rate and incidence rate ratios (IRR) for 
different exposure levels and therefore allows for comparisons across exposure levels. It also 
enables the study of time-dependent effects by splitting the data on time in order to have the 
hazards piecewise constant within predefined time period bands. We used Poisson regression 
in study III and in study IV when looking at IRRs of hospitalizations in breast cancer patients 
as compared with non-breast cancer patients. 
4.3.1.4.3 Flexible parametric models 
Flexible parametric models use restricted cubic splines as the baseline log cumulative hazard 
function. Cubic splines are called restricted because they are forced to be linear before the 
first knot and after the last knot. These parametric models allow for more flexibility as 
compared to other traditional parametric distribution used in survival analysis. By modeling 
the underlying baseline rate parametrically, it is possible to estimate various fitted curves 
from the model, such as event rates over time. Flexible parametric models tend to correlate 
very well with the Cox regression estimates when assuming proportional hazards, but they 
are also particularly effective in modelling time-dependent effects by breaking the 
proportional hazard assumption. Within the flexible parametric modeling framework, it is in 
fact possible to allow covariates to have time-dependent effects by fitting interactions 
between the covariate and time using a second spline function. These interaction splines 
typically use fewer degrees of freedom and are deviation effects from the baseline spline. 
Differences between groups are reported as HRs, but the HRs are now functions of time 
rather than constants  [178, 179]. We used flexible parametric models in study I and study II 
when investigating the time-dependent effects of age and tumor characteristics on the risk of 
death and distant recurrence in women with breast cancer. 
4.3.1.5 Censoring 
Quite often in survival analysis information is not available for all individuals for all the 
study period. Some individuals may start being observed at different time points (entry times) 
and some may drop out or stop being followed (censored) before the end of the study period. 
Censoring can occasionally occur in individuals who enter the study at a later stage and who 
may have already developed the event of interest in the unobserved time before their study 
entry (left censoring). More commonly, individuals (observations) stop being followed before 
the end of the study period: they will be considered as censored because the unobserved event 
may occur later than the observed time for that given individual (right censoring). There is 
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also the possibility to have interval censoring when the true unobserved event for an 
individual lies between two observed time windows, but it is a quite rare situation. 
Censoring is called independent or non-informative when an individual censored at time t is 
representative of all individuals followed till that time. This means that, given certain 
common characteristics measured at baseline (i.e., belonging to the same subgroup), each 
individual observation will have the same chance of being censored up until time t. 
Informative censoring occurs when the mechanisms giving rise to censoring of individual 
subjects are related to the probability of the outcome occurring, therefore biasing the analysis. 
Informative censoring can be partly dealt with by using drop-out events as study termination, 
through imputing techniques, or by the use of sensitivity analyses mimicking best-case and 
worst-case scenarios [180]. 
4.3.1.6 Competing risks 
Another common issue in survival analysis is caused by competing risks. When the outcome 
is defined as cause-specific, like cause-specific death, there will be the need to take into 
account the fact that a person can also die from causes that are not the event of interest. One 
way to deal with this issue is to censor observations at time of death due to causes that are not 
the cause of interest. Assuming that the censoring is non-informative, this is fine when the 
aim is to compare hazard ratios across different covariates in order to detect groups at a 
higher or lower risk of cause-specific death. However, if the aim is to study the real life 
probability that a patient would die from a certain cause by a certain time point, then the risk 
will be probably overestimated. A possible solution to this problem implies the use of so-
called sub-distribution hazards which means to add to each risk set also those observations 
that have already been censored (e.g., individuals who have already died due to other causes). 
In other words, the time in the study of the censored individuals would be considered to be 
larger than all event times in order to modify all risk sets accordingly. This way it would be 
possible to calculate the real life cumulative incidence function (CIF) and better estimate the 
real probability that a person dies from a certain cause or develops a certain condition by time 
t or within a certain time interval [181].  
4.3.2 About standardized incidence/mortality ratios 
Standardized ratios are indirect standardization methods and are used to determine whether 
the occurrence of a certain event (e.g., mortality, incidence) in a specific study population is 
higher or lower as compared with a reference population after adjusting (i.e. standardizing) 
for a chosen variable. In order to calculate the standardized mortality ratios (SMRs) or the 
standardized incidence ratios (SIRs), the observed number of events in the study population 
needs to be divided by the expected number of events taken from the reference population 
(i.e., background number of events). By expected number of events, it is meant the number of 
events that would occur in the study population if the same event rate of the reference 
population occurred in the study population. For its calculation, each variable’s stratum-
specific incidence or mortality rate from the reference population is multiplied by each 
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variable’s stratum of the study population, and then the results are added up. Since age is the 
strongest predictor of incidence and mortality for most health-related outcomes (e.g., breast 
cancer, hospitalizations, bone fractures, infection), it is commonly used as standardization 
variable in the calculation of the SMRs and SIRs, however any other variable can be 
additionally or alternatively used.  
The SIR/SMR will be then calculated by doing a simple ratio between observed and expected 
cases in the study population. Confidence intervals can also be calculated around SMRs and 
SIRs and their statistical significance can be interpreted as for all other measures of 
associations commonly used in epidemiology (e.g., risk ratios, incidence rate ratios and odds 
ratios). If the ratio is more than one, it will mean that the observed cases are more than the 
expected, so in our study population the mortality or the incidence will be considered higher 
than expected. If the ratio is less than one, then it will mean that in the study population the 
mortality or the incidence will be considered lower than expected. And in case the ratio is not 
different from one, the study population will have the expected mortality or incidence.  
Standardized mortality ratios and standardized incidence ratios were used in study IV. 
4.3.3 Study I 
Women were followed from the date of breast cancer diagnosis until date of death, end of 
study (December 31, 2006), or up until 10 years since diagnosis. When considering specific 
causes of death, the time at risk was calculated from the date of breast cancer diagnosis to the 
date of cause-specific death, and women who died as a result of other causes were considered 
censored at date of death.  
Death rates were modeled using flexible parametric models with a restricted cubic spline 
function as baseline death rate [178, 179]. A spline with five degrees of freedom (four 
intermediate knots and two knots at each boundary, placed at quintiles of distribution of 
events) was used for the baseline rate. In all analyses time since diagnosis of breast cancer 
was used as underlying time scale. 
The following clinically relevant variables were included in the models: age group at breast 
cancer diagnosis (<45, 45 to 54, 55 to 64, and 65 to 74 years), calendar period at breast 
cancer diagnosis (1990 to 1994, 1995 to 1999, and 2000 to 2006), tumor size (1 to 20 and 
>20 mm), lymph node status (number of positive lymph nodes: none, one to three, four or 
more), ER status (ER-positive/ER-negative), and treatment. Treatment was categorized 
according to different combinations of surgery with adjuvant therapy as follows: surgery 
only; surgery with radiotherapy; surgery with radiotherapy and chemotherapy; surgery with 
radiotherapy and hormone therapy; surgery with radiotherapy, chemotherapy, and hormone 
therapy; surgery with chemotherapy; surgery with hormone therapy; and surgery with 
chemotherapy and hormone therapy. 
The overall effect of each variable was initially modeled using proportional hazards models. 
Then each tumor characteristic was modeled separately as a time-dependent covariate while 
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adjusting for other variables as non–time-dependent covariates (using three degrees of 
freedom for the interactions). We formally tested the potential three-ways interaction of age 
and tumor characteristics over time since diagnosis using likelihood ratio tests by comparing 
models with and without interaction with age, tumor characteristic, and time. All tests were 
two sided, with significance level of 5%.  
4.3.4 Study II 
Women were observed and contributed to the time at risk from the date of breast cancer 
diagnosis until the date of first distant metastasis (outcome of interest), date of death, 
diagnosis of a second primary cancer, end of study (31 December 2006) or up until 10 years 
since diagnosis.  
The rates of first distant metastasis were modeled using flexible parametric survival models 
with a restricted cubic spline function for the cumulative baseline hazard rate [178, 179]. We 
used a spline with five degrees of freedom (two knots at each boundary and four intermediate 
knots placed at quintiles of the distribution of events) for the baseline rate. Time since breast 
cancer diagnosis was the underlying timescale in all analyses.  
Flexible parametric models allow to post estimate the cumulative risk of developing 
metastasis in the presence of competing risks [182]. The 5-year cumulative risk of first distant 
metastasis since breast cancer diagnosis was estimated for different covariate patterns taking 
into account the competing event “death due to causes other than breast cancer”. The 
cumulative risk of first distant metastasis was also estimated for the period between 5 and 10 
years from diagnosis, conditional upon surviving metastasis-free up to 5 years.  
The following covariates were used in the models: age at breast cancer diagnosis (≤50, 51–
60, 61–74 years), calendar period at breast cancer diagnosis (1990–1994, 1995–1999, 2000–
2006), tumor size (1-20 mm, >20 mm), lymph node status (positive/negative), ER status (ER-
positive/ER-negative) and treatment. Treatment was categorized as local treatment (surgery 
without adjuvant treatment; surgery with radiotherapy only) and systemic treatment (any 
combination of surgery with either chemotherapy or hormone therapy).  
First, time-dependent hazard ratios for the risk of developing first distant metastasis were 
estimated through flexible parametric models by age and tumor characteristics. Then, the 0-5 
years and 5-10 years cumulative risks of first distant metastasis were estimated in the 
presence of competing risk by different sets of covariate patterns.  
4.3.5 Study III 
Different analyses were performed using the Swedish national cohort (see 4.2.2) and the 
Stockholm-Gotland regional cohort (see 4.2.1). 
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4.3.5.1 Swedish national cohort analysis 
In the Swedish national cohort, women were considered at risk until hospitalization due to 
any bone fracture or due to femur fracture (outcomes of interest), date of death, date of 
emigration or 31 December 2009, whichever came first. The analysis was divided by time 
before and after first recorded hospitalization, and by time before and after a breast cancer 
diagnosis, treating breast cancer status as time-varying exposure. Time was split by attained 
age, attained calendar period, and by time since cancer diagnosis only for breast cancer 
patients. Poisson regression was used for modeling hospitalization rates using attained age, 
attained calendar period and breast cancer status in order to compare hospitalization rates 
between women with a breast cancer diagnosis and women without a breast cancer diagnosis.  
4.3.5.2 Stockholm-Gotland regional cohort analysis 
In the Stockholm-Gotland regional cohort, breast cancer patients (study population) were 
followed from date of diagnosis until date of first hospitalization due to any-bone fracture or 
due to femur fracture (outcomes of interest), date of death, date of first distant metastasis, 31 
December 2006 or up until 10 years since breast cancer diagnosis.  
The covariates used in the models were age at breast cancer diagnosis (≤50, 51–60, 61–74 
years), calendar period at breast cancer diagnosis (1990–1994, 1995–1999, 2000–2006), 
tumor size (1-20 mm, >20 mm), lymph node status (positive/negative), ER status (ER-
positive/ER-negative), type of surgery (total mastectomy, partial mastectomy, other) and 
adjuvant treatment. Adjuvant treatment was categorized as any combination of chemotherapy 
without hormone therapy, any combination of hormone therapy without chemotherapy, 
chemotherapy and hormone therapy in any combination, and other.  
Cox regression models assuming proportional hazards were used to check for the possible 
association of different tumor characteristics with the risk of being hospitalized with bone 
fracture.  
The risk of dying after being hospitalized with a bone fracture was also analyzed using Cox 
regression in the same regional cohort. The person-time was divided by time before and after 
first recorded hospitalization due to a fracture. For this analysis the outcomes of interest were: 
death due to any cause, death due to breast cancer and death due to causes other than breast 
cancer. When looking at cause-specific death we censored the analysis for the other causes of 
death.  
4.3.6 Study IV 
We used the Swedish national cohort (see 4.2.2), the LIBRO-1 cohort (see 4.2.3) and the 
CAHRES study population (see 4.2.4) to perform separate analyses. 
4.3.6.1 Swedish national cohort analysis 
In the Swedish national cohort we investigated the rates of hospitalizations due to infection 
and the subsequent death rates comparing breast cancer patients with the general population. 
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Number of person-years at risk for each patient was calculated from the date of breast cancer 
diagnosis until the date of first hospitalization due to an infectious disease, date of death, date 
of emigration or 31 December 2009, whichever came first. We calculated standardized 
incidence ratios (SIRs) and standardized mortality ratios (SMRs) by dividing the observed 
number of hospitalizations due to an infection, and of related deaths, by the expected 
numbers based on the general Swedish female population, with 95% confidence intervals 
(CIs) based on Poisson distribution [183]. The expected numbers of events were calculated 
by multiplying age-specific (5-year interval) and calendar year-specific (5-year interval) 
incidence and mortality rates by corresponding person-years from the general female 
population. Standardized incidence ratios were calculated overall and by time since diagnosis 
modeled as a categorical variable (0-1, 1-2, 2-5, 5-10, >10 years) in order to detect changes 
over time. The analysis was repeated by looking at specific sites of infection as outcomes of 
interest.  
4.3.6.2 CAHRES analysis 
The CAHRES study population was used to check for robustness of our findings in a smaller 
sample with information about additional potential confounders. Incidence rate ratios (IRRs) 
for hospitalizations due to an infection were estimated through Poisson regression with time 
since study entry (i.e. diagnosis date for cases and sampling date for controls) as underlying 
time scale. Age-adjusted IRRs were compared with IRRs from models adjusting for 
additional background risk factors (i.e., BMI, physical activity, smoking, history of 
hypertension and diabetes).  
4.3.6.3 LIBRO-1 analysis 
The LIBRO-1 regional cohort was used to study the association of tumor characteristics and 
treatment with the risk of being hospitalized with an infection. Poisson regression was used to 
model rates of hospitalization due to an infection with time since diagnosis as the underlying 
time scale. The covariates used in the analysis were tumor size (<10 mm, 10-20 mm, 
>20mm), histological grade (low, intermediate, high),  ER status (ER-negative, ER-positive), 
number of  positive lymph nodes (0, 1-5, >5); number of dissected lymph nodes (<5, 5-10, 
>10), endocrine and chemotherapy (none, endocrine only, chemo only, endocrine plus 
chemotherapy), radiation therapy (none, breast only, breast plus nodes, nodes only, organ 
unspecified), surgery (partial mastectomy, total mastectomy).  Adjustment for age at 
diagnosis (years) with mutual adjustment for other tumor characteristic and treatment 
variables was performed in all analyses.  
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5 MAIN RESULTS 
5.1 STUDY I 
Breast cancer was the underlying cause in 1,188 (64.2%) of the 1,849 deaths occurred in the 
Stockholm-Gotland regional cohort of 12,850 women diagnosed with breast cancer in the 
period 1990-2006 and followed up for a maximum of 10 years. Breast cancer accounted for 
226 (95%) of the 238 deaths among women younger than 45 years at diagnosis while, among 
women 65-74 years at diagnosis, an underlying cause other than breast cancer accounted for 
the majority (n=390, 55%) of the 703 deaths. The proportion of circulatory system disorders 
and of other cancers as underlying cause of death increased with age at diagnosis (from 0.4% 
and 2.1% in less than 45 years, to 24.0% and 14.9% in 65-74 years, respectively).  
Breast cancer-specific death rates peaked within 5 years from diagnosis. They were higher 
overall in women younger than 45 years at diagnosis, however they converged with the ones 
observed in the older age groups at 10 years of follow-up (15 per 1,000 person-years). The 
rates of death due to circulatory system disorders and due to cancers other than breast cancer 
increased with age and time since diagnosis.  
The risk of dying due to any cause increased with age at diagnosis, while the risk of breast 
cancer-specific death was higher in women younger than 45 years at diagnosis as compared 
with women 45-54 years at diagnosis (HR=1.2 95% CI: 1.0-1.4). Women with positive 
lymph nodes at breast cancer diagnosis were at significantly increased risk of breast cancer-
specific (and overall) death within 10 years from diagnosis (HR=2.4; 95% CI: 2.0-2.9 for 
patients with 1-3 positive lymph nodes at diagnosis; HR=5.9; 95% CI: 4.9-7.1 for patients 
with 4 or more positive lymph nodes at diagnosis) (Table 1). Women with tumor size larger 
than 20mm or with ER-negative tumor were also at increased risk of breast cancer-specific 
and overall death within 10 years from diagnosis (Table 1), however not for the full period as 
shown in the time-dependent effects analysis (Figure 13b). 
The risk of dying from a circulatory system disorder was higher in older as compared with 
younger patients. The risk of dying due to a circulatory system disorder was significantly 
higher in women with positive lymph nodes at diagnosis (HR=2.0; 95% CI: 1.4-2.9 for 
women with 1-3 positive nodes; HR=1.9; 95% CI: 1.0-3.4 for women with 4 or more positive 
nodes). The risk of dying from a circulatory system disorder was higher also for women with 
a tumor size larger than 20mm (HR=1.5; 95% CI: 1.1-2.1) but it was not affected by ER 
status (HR=0.8; 95% CI: 0.5-1.3) (Table 1). 
Tumor characteristics at breast cancer diagnosis did not affect the risk of dying from cancers 
other than breast (Table 1). 
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Table 1. Hazard ratios (HRs) for different causes of death by tumor characteristics among 
breast cancer patients in the Stockholm-Gotland Breast Cancer Register, 1990-2006. 
 Breast cancer  Circulatory 
system disease  
Other cancerb All-cause  
  
HRb 
 
95% CI 
 
HRb 
 
95% CI 
 
HRb 
 
95% CI 
 
HRb 
 
95% CI 
         
Positive nodes         
0  1.0 - 1.0 - 1.0 - 1.0 - 
1-3 2.4 2.0-2.9 2.0 1.4-2.9 1.3 0.8-1.9 2.1 1.8-2.4 
≥ 4 5.9 4.9-7.1 1.9 1.0-3.4 1.6 0.9-3.0 4.3 3.7-5.0 
         
Estrogen receptor         
ER+  1.0 - 1.0 - 1.0 - 1.0 - 
ER- 2.1 1.8-2.4 0.8 0.5-1.3 1.5 0.9-2.4 1.8 1.6-2.1 
         
Tumor size, mm         
1-20 1.0 - 1.0 - 1.0 - 1.0 - 
> 20 1.9 1.7-2.2 1.5 1.1-2.1 1.0 0.7-1.4 1.7 1.5-1.9 
         
a - estimated from a flexible parametric survival model assuming proportional hazards, i.e. constant 
HRs for all variables throughout the 10-year follow-up. The HRs were adjusted for all variables in 
the column and time-since-diagnosis (the underlying time scale) 
b - ”Other cancer” include all cancers other than breast cancer 
 
When looking at time-dependent effects of tumor characteristics on the risk of dying from 
breast cancer, women with positive lymph nodes at breast cancer diagnosis remained at 
significantly increased risk of breast cancer-specific death for 10 years since diagnosis 
(Figure 13a). ER-negative patients were at significantly increased risk of dying in the first 5 
years since breast cancer diagnosis as compared with ER-positive patients. After 5 years of 
follow-up this difference was not any more significant among the survivors (HR=1.3; 95% 
CI: 0.9-1.7 at 5 years from diagnosis) (Figure 13b). Patients with a tumor larger than 20mm 
were at increased risk of dying compared to patients with tumor size less than 20mm up to 
about 8 years since breast cancer diagnosis. Age did not significantly affect time dependent 
effects of tumor characteristics on risk of death. 
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Figure 13a. Time-dependent hazard ratios (HRs) for dying from breast cancer by lymph 
node status in the study population. 
 
Figure 13b. Time-dependent hazard ratios (HRs) for dying from breast cancer by ER status 
in the study population. 
 
5.2 STUDY II 
In the Stockholm-Gotland regional cohort, 995 (10.4%) women developed distant metastasis 
during the study period. Overall, metastasis to the skeleton (32.5%) and multiple sites of 
metastasis (28.3%) were the most frequent presentations of distant metastasis within 10 years. 
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The proportion of first distant metastasis to the skeleton significantly increased over time 
since breast cancer diagnosis, while the proportion of central nervous system (CNS) and liver 
metastasis significantly decreased (Figure 14).  
 
Figure 14. Distribution of sites of first distant metastasis by time since breast cancer 
diagnosis. 
Women with positive lymph nodes at breast cancer diagnosis were still at increased risk of 
developing distant metastasis at 10 years from diagnosis (HR=2.6; 95% CI: 1.9–3.5). Women 
with ER-negative tumors were at increased risk of distant metastasis compared to women 
with ER-positive tumors only in the first 5 years since breast cancer diagnosis (HR=1.4; 95% 
CI: 1.1-1.7, at 5 years; HR=0.9; 95% CI: 0.6-1.4, at 10 years). Patients with a tumor larger 
than 20mm at diagnosis were still at increased risk of metastasis at 10 years since breast 
cancer diagnosis (HR=1.5; 95% CI: 1.1–2.0). 
The cumulative incidence of distant metastasis varied across different ages and tumor 
characteristics and over time since diagnosis. After taking into account competing risk, 
women youngers than 45 years, lymph node positive, ER-negative, and with tumor larger 
than 20mm at breast cancer diagnosis had more than 60% risk of developing distant 
metastasis within 10 years, while women aged 45-54 years with lymph node positive, ER-
positive, tumor size less than 20mm at diagnosis had about a 20% risk of developing 
metastasis within 10 years (Figure 15). In the period 5–10 years of follow-up, women with 
ER-positive, lymph node-positive and ≤20 mm tumors at breast cancer diagnosis showed the 
highest risk of distant recurrence.  
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Figure 15. Cumulative incidence function (CIF) for the development of first distant 
metastasis over time since diagnosis in lymph node-positive breast cancer patients taking 
competing risk into account.  
 
5.3 STUDY III 
Of the 6,939 hospitalizations due to bone fracture diagnosed among breast cancer patients in 
Sweden in the period 1990-2009, 2,701 (38.9%) were reported as femur fractures, 1,474 
(21.3%) as other lower limb fractures, and 1,702 (24.5%) as upper limb fractures. The 
proportion of hospitalizations due to femur fracture over the total amount of hospitalizations 
due to any-bone fracture increased with age and consequently with time since breast cancer 
diagnosis. The overall rate ratios of hospitalizations due to any bone fracture, and due to 
femur fracture alone, were 1.25 (95% CI: 1.23-1.28) and 1.21 (95% CI: 1.17-1.25), 
respectively. These rate ratios were gradually decreasing over time since breast cancer 
diagnosis remaining significant for over 10 years (Figure 16), and were significantly 
increased in all age groups.  
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Figure 16. Rate ratios for hospitalizations due to bone fracture after breast cancer by time 
since diagnosis.  
Tumor characteristics did not differentially affect the risk of being hospitalized with a bone 
fracture among breast cancer patients. The risk of being hospitalized with a bone fracture was 
significantly increased in women older than 60 years at breast cancer diagnosis as compared 
with younger breast cancer patients.  
Breast cancer patients were at increased overall risk of dying after a being hospitalized with a 
bone fracture (HR=1.81; 95% CI: 1.46-2.25), particularly if diagnosed at an older age. A 
hospitalization due to a bone fracture following breast cancer diagnosis did not significantly 
affect the risk of dying from breast cancer (HR=0.92; 95% CI: 0.63-1.35), while it 
significantly increased the risk of dying due to causes other than breast cancer (HR=3.14; 
95% CI: 2.39-4.14). The risk of dying after being hospitalized with a femur fracture was even 
more increased (HR=2.60; 95% CI: 1.94-3.48), in particular when looking at the risk of dying 
from causes other than breast cancer (HR=4.00; 95% CI: 2.75-5.72) (Table 2). 
Table 2. Risk of dying after any-bone and femur fracture hospitalization in breast cancer 
patients. 
Causes of death Any-bone fracture Femur fracture 
 HR (95% CI) HR (95% CI) 
Overall death 1.81 (1.46-2.25) 2.60 (1.94-3.48) 
Breast cancer-specific death 0.92 (0.63-1.35) 1.43 (0.85-2.39) 
Other cause of death 3.14 (2.39-4.14) 4.00 (2.75-5.72) 
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5.4 STUDY IV 
In the nationwide cohort we found an increased risk of being hospitalized with an infection 
for breast cancer patients as compared with the general population (SIR=1.74; 95% CI: 1.70-
1.78). In particular, SIRs were highest in the first year after diagnosis and remained 
significantly increased after 10 years since diagnosis (SIR=1.30; 95% CI: 1.24-1.36) (Figure 
17). This increased risk over 10 years since breast cancer diagnosis was particularly high for 
infections of the skin (SIR=1.68; 95% CI: 1.50-1.88).  
 
Figure 17. SIRs for hospitalizations due to an infection over time since breast cancer 
diagnosis comparing breast cancer patients with the general population. 
Breast cancer patients had a higher infectious disease-specific mortality compared with the 
general female population. In the nationwide cohort, 328 deaths due to infection were 
reported, a number that is higher than the expected (n=290) calculated in the general Swedish 
female population (SMR=1.17; 95% CI: 1.02-1.26).  
In the LIBRO-1 regional cohort of breast cancer patients, the risk of being hospitalized with 
an infection was higher for patients with a more aggressive pattern of tumor characteristics at 
breast cancer diagnosis (high histological grade, large tumor size, positive lymph nodes, ER-
negative status) (Table 3). The risk of sepsis was higher in patients with ER-negative, 
positive lymph nodes and high histological grade tumors, while risk of skin infections was 
higher in patients with tumor size larger than 20mm (IRR=2.04; 95% CI: 1.14-3.62) and with 
more than 5 positive lymph nodes at diagnosis as compared to none (IRR=2.38; 95% CI: 
1.26-4.51). Undergoing chemotherapy was significantly associated with risk of sepsis 
(IRR=4.35; 95% CI: 1.84-10.30), while receiving loco-regional radiation therapy was 
significantly associated with infections of the skin (IRR=2.81; 95% CI: 1.19-6.63). 
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Table 3. Association of tumor characteristics with the risk of being hospitalized with an 
infection in breast cancer patients (regional cohort, N = 8,111).  
 
Regional cohort  IRR (95% CI) 
 N Any infection Skin infection Sepsis 
Tumor characteristic 1     
Size in mm     
  <10 2042 REF (1.00) REF (1.00) REF (1.00) 
  10-20 3685 1.08 (0.90-1.31) 1.54 (0.90-2.64) 1.23 (0.83-1.82) 
  >20 2384 1.26 (1.03-1.55) 2.04 (1.14-3.62) 1.35 (0.88-2.07) 
Histological grade 
(Elston) 
    
  Low 989 REF (1.00) REF (1.00) REF (1.00) 
  Moderate 2582 1.27 (0.96-1.69) 1.11 (0.59-2.08) 1.63 (0.82-3.23) 
  High 1510 1.47 (1.08-2.00) 0.83 (0.40-1.73) 2.12 (1.03-4.33) 
ER status     
  Positive 5476 REF (1.00) REF (1.00) REF (1.00) 
  Negative 937 1.34 (1.07-1.66) 1.08 (0.59-2.00) 1.92 (1.30-2.82) 
No. positive lymph 
nodes 
    
  0 5117 REF (1.00) REF (1.00) REF (1.00) 
  1-5 2267 1.26 (1.06-1.49) 1.18 (0.75-1.85) 1.41 (1.01-1.96) 
  >5 454 2.14 (1.65-2.78) 2.38 (1.26-4.51) 1.87 (1.12-3.14) 
Abbreviations: IRR = incidence rate ratio; CI = confidence interval. All analyses are adjusted for age at 
diagnosis (years) and mutually adjusted for the variables listed (tumor characteristics and treatment 
separately).   
1 Missingness on individual variables < 4%, except for histological grade (37.4%, N = 3030) and ER status 
(20.9%, N = 1698).  
 50 
6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Strengths 
The use of Swedish population-based registers linked by personal identification number has 
virtually eliminated loss to follow-up in our studies and minimized the possibility of related 
bias. The information available in the registers is quite exhaustive with detailed information 
on tumor characteristics and treatment allowing comprehensive and powerful analyses on risk 
stratification. The large breast cancer cohorts used were followed up to at least 10 years with 
accurate and complete information, enabling to apply a comprehensive design and 
methodology to check for differences in risk within different subtypes of breast cancer 
patients and between breast cancer patients and the general population.  
We studied relevant health outcomes of women with breast cancer over time since diagnosis 
by using different measures and by providing an overall picture of risks over time: we used 
rates (e.g., rates of death, rates of first distant metastasis, rates of hospitalization), ratios (e.g., 
hazard ratios, incidence rate ratios, standardized incidence ratios, standardized mortality 
ratios) and absolute risks (e.g., cumulative incidence). Not assuming proportional hazards in 
some analyses allowed for the study of the interaction of tumor and patient characteristics 
with time since diagnosis, providing a more accurate picture of the follow-up of these 
patients. We were also able to take competing risk into account when looking at the absolute 
risk of distant metastasis in different subtypes of patients. Swedish national and regional 
practices for breast cancer diagnosis and treatment during the study period have remained 
rather consistent according to updated international and national guidelines and this may have 
contributed to more homogeneity in the study populations for some of the additional factors 
we were not able to take into account in the analyses.  
6.1.2 Random error 
The random error can always influence the validity of the conclusions of a study and in 
particular it can affect the precision, especially when a study population is rather small. As 
opposed to systematic errors, where the measurement is systematically inaccurate due to an 
inherent bias, the estimates affected by random errors are distributed around the true value. In 
statistics, the hypothesis of an association of two variables observed in the study sample is 
usually tested against the null hypothesis of no association. The output of a statistical test is 
usually a p-value which is the probability, under the assumption that the null hypothesis of no 
association is true, of obtaining a result equal or more extreme to the one observed. The lower 
the p-value, the less likely is that what we observed is true under the null hypothesis (i.e., 
there is no association). A threshold under which the null hypothesis is rejected is often 
chosen and it is commonly set at α=0.05 for single comparisons. The random error may cause 
two types of mistakes in statistical testing: type I error (rejecting the null hypothesis when it 
is true) and type II error (accepting the null hypothesis when it is false). The probability of 
committing a type I error is usually called α, while the probability of committing a type II 
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error is usually called β. Since we used large population-based registers in all our studies we 
do not think that the random error is a particular issue of concern in our four studies. 
6.1.3 Selection bias 
Selection bias in epidemiology is a systematic error that often occurs when the subjects 
(observations) included in a study (i.e., study population) are not representative of the 
population the researchers want to infer about (i.e., target population). Selection bias can 
affect both the internal and the external validity of a study. More specifically, selection bias 
occurs when the selection/participation probabilities are influenced by exposure or disease 
status: for instance, there will be selection bias if women diagnosed with cancer who have a 
worse prognosis are more likely than women with a better prognosis to be recruited in a study 
on the risk of death from cancer. Selection bias in prospective studies can also occur after the 
recruitment, or selection phase, if participants drop out from the study not randomly: a typical 
example can occur with loss to follow-up. Here below, some examples of selection biases 
that could potentially concern some of our studies.   
6.1.3.1 Informative censoring 
Informative censoring occurs when participants are censored due to reasons related to the 
study [184]. In our studies we performed censoring for death due to causes other than breast 
cancer (study I and study III), or due to all causes of death (study II-IV). This censoring 
would be informative if subjects who died during the follow-up (i.e. censored observations) 
were more or less likely to develop the outcome of interest (e.g., develop distant metastasis) 
than those who did not die before the occurrence of the event (i.e. not censored observations). 
The risk of informative censoring increases with length of follow-up time [185]. 
In study I, we found that tumor characteristics are not good predictors of causes of death 
other than breast cancer, therefore we consider the censoring performed largely non-
informative for the main analysis carried out on risk of breast cancer-specific death. In study 
II, we did not consider in the analysis the women who were reported to die from breast cancer 
without developing any distant metastasis, as it was considered unreliable. Thus, informative 
censoring in this case could have only occurred if dying from causes other than breast cancer 
were somehow associated with the risk of distant metastasis, which is difficult to imagine 
unless we assumed that a more aggressive disease would be treated more aggressively and 
many women would die from the side effects of the treatment within ten years. In study III 
and IV we cannot completely rule out the risk of some informative censoring, as patients who 
died (or who developed metastasis in study III) before being hospitalized for bone fracture or 
infection may have also been at significantly increased (or decreased) risk of developing the 
outcome, as compared to the breast cancer patients who were not censored.  
6.1.3.2 Competing risks 
When predicting the probability or the risk of an event by a certain time t, one has also to take 
into account the possible occurrence of other competing events that may prevent the event of 
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interest from happening. This issue was described in the methods section as a typical problem 
in survival analysis when trying to estimate the absolute risk of an event by a certain time 
(see 4.3.1.6). In study II we tried to predict the cumulative incidence function (CIF) of distant 
metastasis for different subgroups of breast cancer patients according to different exposure 
levels of age, treatment and tumor characteristics at diagnosis. Being aware of the risk of 
overestimating the real-world cumulative incidence of distant recurrence over time, we took 
into consideration in the analysis the competing risk of dying during the study period before 
developing distant metastasis. Figure 18 shows the cumulative incidence functions for the 
outcome of interest (i.e., distant recurrence) and the competing risk (i.e., death from cause 
other than breast cancer) stacked on top of each other over time since diagnosis, enabling to 
see the relative contribution of the two events over time (Figure 18). 
 
Figure 18. Stacked graph of a cumulative incidence function (CIF) showing the relative 
contribution of competing risk of death when looking at distant recurrence in breast cancer 
(BC) patients as an event. 
6.1.3.3 Choice of reference population 
When using the general population as the reference population in order to obtain the expected 
number of deaths for the standardized mortality ratios calculation or the expected incidence 
for the standardized incidence ratios calculation, it is important to consider that this may be a 
source of bias if the general population were not representative of the unexposed population. 
This is due to the fact that the exposed population (e.g., women with breast cancer) is also 
part of the general population. In order for a bias to occur, there either should be a high 
prevalence of the exposure in the population, or high values of standardized mortality ratios 
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or standardized incidence ratios [186]. The direction of this bias is towards the null, so any 
value can either be equal or more extreme than the one found. In study IV we used 
standardized incidence and mortality ratios and the Swedish general female population as a 
reference for the expected number of hospitalizations. We cannot therefore rule out the 
conservative effect of this bias on our estimates that however may be even larger than those 
we have shown. 
6.1.4 Information bias 
Information bias is another type of systematic error and occurs when a measurement of 
exposure or of an outcome is systematically inaccurate. It is also commonly known as 
misclassification due to the consequent incorrect classification of exposure status and/or 
cases-control (i.e., outcome) status. Misclassification can typically be differential (i.e., 
affecting exposed and unexposed, or cases and controls, in an uneven way) and lead to a bias 
that will have a clear direction, or non-differential (i.e., similarly affecting exposed and 
unexposed, or cases and controls) and bias the measure of association towards the null (no 
association).  
6.1.4.1 Misclassification of tumor characteristics at baseline 
If the accuracy in the measurement of the exposure status is carried out differentially between 
those who will develop the outcome of interest and those who will not, there will be a bias. 
The data sources we used have a very good level of completeness of information (see 4.1). In 
particular, in the Stockholm Gotland regional cohort (study I-III), the information about age 
at diagnosis, date of diagnosis and treatment combination was available for virtually every 
individual, information on number of positive lymph nodes at diagnosis and tumor size was 
available for about 95% and 98% of patients, respectively and information on ER status was 
available for about 80%. The information contained in our data sources has been validated 
and has shown a very good level of accuracy for most of the variables (see 4.1). The 
measurement of tumor characteristics is routinely performed and reported by trained 
professionals, and despite some heterogeneity in some specific measurement in the past, we 
believe that any such heterogeneity will not be differentially distributed across different levels 
of exposure. 
6.1.4.2 Lead-time bias 
Lead time bias may typically occur when assessing the survival of a screened population 
versus an unscreened population. Screening allows for an earlier diagnosis of a disease in 
order to anticipate the treatment and achieve better results with a less aggressive therapy. 
Patients who undergo screening are thus diagnosed earlier as compared to patients who are 
diagnosed with the disease only after the onset of the symptoms. This may cause an 
overestimation of the survival time of the screened patients due to the anticipation of 
diagnosis. The time between early diagnosis with screening and time where diagnosis would 
have occurred without screening is called “lead time”. Lead time should not be considered 
increased survival due to screening, but just a simple artifact due to the anticipation of 
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diagnosis among screened patients (Figure 19). Lead time bias is particularly important when 
population screening campaigns, such as those for some solid cancers (e.g., breast cancer), 
are in place. 
 
Figure 19. Lead-time bias in screening-detected chronic diseases. 
The effect of mode of detection was not assessed in our studies, therefore lead-time bias 
cannot be ruled out. The Swedish Board of Health and Welfare recommended 
mammographic screening implementation in 1985. By 1990 up to 93% of women in target 
age groups had been invited to screening, and by 1997 nationwide coverage was obtained. 
The mammographic screening officially started in Stockholm in 1989 for women aged 50-69 
years and was recommended to be performed every second year. Screening is currently 
offered to all women aged 40-74 years in 10 out of 21 counties in Sweden [187]. The 
participation rate to mammographic screening in Sweden is the highest recorded in any 
country, between 75-85% currently; in particular, in the area of Stockholm the participation 
rate was 72% as early as 1995-96 [188]. Given the high participation rate and the good level 
of accuracy in early diagnosis of the Swedish health care system, we believe that lead-time 
bias may not have differentially affected our study population during the study period. 
Although unable to rule out some effect of this bias on our estimates, we do not believe this 
effect to be particularly pronounced.  
6.1.4.3 Misclassification of the outcome  
When dealing with specific health outcomes like underlying cause of death (e.g., death due to 
a circulatory system disorder) or main diagnosis of hospitalization (e.g., femur fracture), there 
might be some degree of inaccuracy in the ICD coding, that may bias the results if 
misclassification has occurred. While acknowledging the good quality of the data sources 
used in our studies (see 4.1), we additionally tried to reduce the impact of this potential 
source of information bias by being more inclusive and using larger disease categories when 
selecting the ICD codes. 
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In study I the analysis of cause-specific mortality statistics may be affected by 
misclassification of underlying main causes of death. We used cause-specific outcomes like 
“death due to diseases of the circulatory system”, in which ischemic heart disease accounted 
for approximately 45% of cause-specific deaths and cerebrovascular diseases for 
approximately 20%. We also used “death due to cancers other than breast cancer”. Previous 
studies have already shown that the use of underlying cause of death from the Swedish 
Causes of Death Register is overall reliable [168, 189], although one can never exclude some 
residual misclassification. In study II, the date of diagnosis of distant metastasis might be 
subject to timing of clinical work-ups and type of follow-up. In addition, the site of first 
distant metastasis could be affected by detection bias as some locations might cause earlier 
symptoms than other or may be detected earlier; we therefore decided not to focus on specific 
site of metastasis in the main analysis. In study III we considered that hip fractures, and more 
in general femur fractures, usually require hospitalization, therefore we believe that our 
analysis captured most such cases; however when looking at all fractures, there may be some 
underestimation in the number of other fractures associated with bone loss, like wrist or 
vertebral fractures that can also be treated in an outpatients setting. There are some potential 
limitations related to the difficulty to discern between pathological fractures (due to bone 
metastasis from the primary breast cancer) and other bone fractures, in case bone metastases 
were not correctly and timely reported into the register. However, the diagnostic validity of at 
least femur fractures is considered very high in Swedish Inpatient Register with an estimated 
specificity quite close to 100% [190]. Also in study IV there was some concern about 
potential misclassification of the outcome. A recent evaluation of the Swedish National 
Inpatient register indicated high coverage and validity for most diagnoses [169], however 
infectious diseases have not extensively been validated in this particular setting. Previous 
studies in selected (patient) populations show that using main inpatient diagnosis is suitable 
for monitoring hospitalizations due to infection [191, 192], but the sensitivity seems to vary 
by organ site and appears to be the lowest for sepsis (about 50%) [193]. Furthermore, there 
are some indications that the sensitivity might depend on age, comorbidities and disease 
severity [194], and lower sensitivity estimates have been reported with older age, severe 
comorbidity and presence of immunosuppression. This, however, should result in more 
conservative risk estimates rather than producing spurious ones.  
6.1.4.4 Referral bias and health seeking behavior 
Having been diagnosed with cancer might make breast cancer patients more likely to be 
hospitalized than other individuals from the same area, period and age group, because of 
increased cautiousness of the patient or of the physicians. Compared with the general 
population, breast cancer patients might therefore be more likely to be hospitalized because 
of health-seeking behavior and/or referral bias. This could explain the initial increase 
observed in study III and study IV in rate ratios for hospitalizations due to bone fracture and 
in SIRs hospitalizations due to infection. However, it hardly explains the increased risk of 
hospitalization observed also beyond 5 years since diagnosis, nor it explains the observed 
increase in mortality which is less subject to this type of bias. Also, the associations did not 
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significantly differ when using inpatient individuals as reference. Hence, it seems unlikely 
that this type of bias fully explains the observed associations in study III and study IV. 
6.1.5 Confounding 
Confounding is a spurious association between an exposure and an outcome of interest due to 
a third variable. A confounder is defined as a variable that is causally associated with the 
outcome of interest in the unexposed and that is also associated with the exposure in the 
source population (Figure 20). Another fundamental characteristic of a confounder is that it 
should not be an intermediate cause between the exposure and the outcome of interest, in 
other words it does not have to be a factor along the causal pathway between the exposure 
and the outcome. Confounding is a typical problem in observational studies and is the main 
reason why they are generally considered inferior to experimental study designs where 
randomization can be applied in order to get rid also of residual confounding. Confounding 
can be adjusted in the analysis given that information on potential confounders was 
previously collected, as opposed to bias where one can just tell the direction of the systematic 
error without being able to adjust for it in the analysis. In observational studies, confounding 
is usually dealt with adjustment carried out by stratification, standardization or modelling. If 
measurement of potential confounders is not possible, this will become residual or 
unmeasured confounding and will potentially bias the findings.  
                       
Figure 20. Example of a relationship between confounder, exposure and outcome variables. 
In our studies we considered some of the measurable factors that can be causally linked to the 
main outcomes of interest (death, distant metastasis, bone fracture-related hospitalization, 
infection-related hospitalization). We included in most of our models age at breast cancer 
diagnosis, calendar period, tumor size, lymph node status, ER status and treatment 
combination. We did not take into account other factors like comorbidities (e.g., concomitant 
severe diseases for mortality, osteoporosis for bone fractures, diabetes for infections); specific 
medications or treatments (e.g., bisphosphonates and aromatase inhibitors for bone fractures, 
corticosteroids for infections and bone fractures); diagnostic and invasive procedures (e.g., 
venous catheter use and blood transfusions); personal behaviors (e.g., smoking and alcohol 
consumption) due to the lack of available information in the data sources used. Moreover we 
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could not take into account specific agents introduced in the management of breast cancer 
patients during the study period, like aromatase inhibitors and bisphosphonates or like 
trastuzumab in HER2-positive cancers, and also changes in the prescription and use of 
specific chemotherapeutic agents. Some of these factors can potentially affect the risk of bone 
fracture and infection, and also the overall survival especially at an older age [195-197]. We 
partly evaluated the impact of potential residual confounding only in study IV, by running 
additional analyses in a case-control study population (CAHRES study, see 4.2.4) with more 
detailed information on background risks, and we found that the estimates were not affected 
by adding these additional factors in the model (i.e., BMI, physical activity, smoking, history 
of hypertension and diabetes). 
One should always be careful when choosing what to adjust for confounding, since there may 
be instances when this is not appropriate as when one factor is on the causal pathway between 
exposure and outcome. In our studies, the high degree of correlation between tumor 
characteristics and treatment has made it quite challenging to disentangle and isolate each 
respective effect. The type of adjuvant treatment is generally chosen based on type of 
surgery, tumor grading and staging and on receptors status, together with other clinical and 
general considerations, like for instance the age or the general conditions of the patient. 
Treatment can therefore be considered partially on the causal pathway between tumor 
characteristics and outcome. In all studies, we noticed a consistent robustness of the estimates 
when adjusting or not adjusting by adjuvant treatment. We also need to stress that the effect 
of treatment is generally better studied within an experimental study design where 
randomization minimizes the risk of confounding by indication. 
6.1.6 Generalizability 
As in all studies requiring a long follow-up, the estimated long-term risk of a specific health 
outcome might not reflect the current risk for newly diagnosed patients: in particular, 
adjuvant treatment has been changing over time and recently diagnosed patients may not 
show the same risk patterns as the ones observed in our studies. 
 
6.2 FINDINGS AND INTERPRETATION 
6.2.1 Study I 
The effects of ER status, lymph node status, and tumor size on the risk of dying from breast 
cancer were all time-dependent. Previous studies based on the Surveillance, Epidemiology, 
and End Results (SEER) database reported that the difference in survival associated with 
hormonal receptor status may persist up to 11 years after diagnosis [54], and that women with 
ER-negative tumors were consistently more at risk of dying regardless of other tumor 
characteristics [55]. In our study we were able to assess the effect of ER status on the risk of 
dying from breast cancer while taking into account hormone treatment. We found that, after 5 
years since diagnosis, ER status was not significantly associated with the risk of dying from 
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breast cancer. Our results are also in agreement with clinical trials showing a low but 
continuous risk of relapse from 5 to 15 years after primary diagnosis in ER-positive patients, 
and most relapses occurring from 2 to 3 years since diagnosis in ER-negative patients [5, 
198]. One possible explanation of our findings could be that ER-negative patients, who 
survive more than 5 years, are the fittest independent of other known prognostic factors. 
The effect of lymph node status on survival remained significant for up to 10 years after 
breast cancer diagnosis and accordingly we can infer that lymph node status at diagnosis is a 
long-term prognosticator of survival as previously reported [199]. Previous research reported 
that, for each additional positive lymph node, the risk of breast cancer–specific death 
increases by 6%, and each millimeter increase in tumor size increases the risk by 
approximately 1% [200]. Recent findings showed that even micrometastasis to the lymph 
nodes predicts prognosis [201-203]. In our study population, having 1-3 versus 4 or more 
positive lymph nodes at diagnosis had a positive effect on survival in the first 5 years since 
diagnosis, while after 5 years this effect gradually disappeared. This could again be explained 
by survival of the fittest in the group with poorer prognosis (i.e., 4 or more positive lymph 
nodes at diagnosis) and by delayed mortality within the group initially considered to have a 
better prognosis (i.e., 1-3 positive lymph nodes at diagnosis). A similar pattern was seen for 
tumor size, although the magnitude of the effect was less pronounced.  
Circulatory system disorders were an important cause of death in our study population: about 
45% were caused by ischemic heart disease and about 20% by cerebrovascular disease. 
Deaths resulting from circulatory system disorders might partly reflect the toll of stress on 
elderly women diagnosed with a severe disorder [204]. In fact, women diagnosed with less 
favorable tumor characteristics (large tumor size or positive nodes) showed a borderline 
increased risk of dying from circulatory system disorders, and this effect was more 
pronounced within the first year since diagnosis. Finally, the risk of dying from cancers other 
than breast cancer was not significantly associated with tumor characteristics. 
6.2.2 Study II 
In our cohort, up to one-third of distant metastasis was diagnosed in the skeleton. This 
proportion significantly increased over time since diagnosis, whereas the proportion of 
metastasis to the liver and central nervous system (CNS) significantly decreased. This seems 
to reflect the natural history of distant recurrences, as women with ER-positive tumors more 
often develop metastasis later during follow-up (and more preferably to the skeleton), 
whereas women with ER-negative tumors more often tend to develop liver and CNS 
metastasis earlier [205].  
Lymph node status at breast cancer diagnosis was significantly associated with the risk of 
distant recurrence for at least 10 years, whereas ER status at diagnosis was significantly 
associated with risk of distant recurrence only in the first 5 years [206]. The similarity with 
the pattern observed in the same cohort when looking at the risk of dying from breast cancer 
  59 
(study I) suggests that the development of distant metastasis is still a predictor of poor 
prognosis in breast cancer patients [207, 208].  
The cumulative risk of first distant metastasis was still relevant for most patients from 5 years 
since breast cancer diagnosis onwards. Patients with ER-positive and lymph node-negative 
tumors were at rather low but similar cumulative risk of distant recurrence over the different 
periods of follow-up 0-5 years and 5-10 years. More clinical attention should however be 
given to other subgroups of patients that were found to be at a higher risk. In particular, ER- 
and lymph node-positive patients with tumors larger than 20mm still had a risk higher than 
10% to develop distant metastasis in the period between 5 and 10 years since breast cancer 
diagnosis. Although evidence supporting the change of current practice is rather weak [209], 
following future improvements in prevention and treatment of metastatic breast cancer, a 
differential follow-up of subgroups of breast cancer patients could be considered, given 
remarkably different risks of spreading, natural histories and treatment options available. 
6.2.3 Study III 
In the Swedish national cohort, breast cancer patients were at long-term increased risk of 
being hospitalized with a bone fracture. This risk remained significantly increased for more 
than 10 years since diagnosis. Treatment and severity of the disease may explain this 
difference for the period shortly after breast cancer diagnosis, but it can hardly explain it at 10 
years or further. Bone tissue is sensitive to sex hormones [210] and previous studies have 
clarified the important role of hormonal treatment in affecting bone metabolism [85-87, 89, 
120, 122, 123, 211]. While tamoxifen has a protective effect against osteoporosis and 
subsequent bone fractures [122, 211], other hormonal treatments, like aromatase inhibitors, 
can lead to a negative impact on bone metabolism and to a higher risk of fractures in women 
with breast cancer, especially in combination with menopause and older age [211-214]. 
Prostate cancer patients showed an increased risk of fractures compared to the general 
population, especially if treated with an androgen deprivation therapy [215-217]. There were 
also some studies unable to show a significantly increased risk of bone fracture in women 
with a previous breast cancer diagnosis [216, 218].  
In our regional cohort of breast cancer patients, no differential effect of tumor characteristics 
and adjuvant treatment combination on the risk of being hospitalized for a bone fracture was 
found. The correlation between tumor characteristics and adjuvant treatment combination, the 
lack of information about specific administered agents, duration of treatment and dose, and 
the combination of agents with different effects on bone metabolism may have also hidden 
any existing differential association.  
We finally found an increased overall risk of death after a bone fracture hospitalization (not 
only after a hip fracture hospitalization) in women with a previous breast cancer diagnosis. 
This increased risk seems completely driven by an increased risk of dying from causes other 
than breast cancer, in particular among women 61-74 years at breast cancer diagnosis. 
Previous studies showed that osteoporotic fractures are associated with a 1.4-2.4-fold 
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increased risk of death for at least 5 years and this risk remains significantly increased for at 
least 10 years after a hip fracture [119]. In older people, hip fractures are associated with a 5- 
to 8-fold increase in mortality within 3 months, and a 2-fold increase within a year [219, 
220]. Hip fractures can be associated with complications like pressure ulcers, deep vein 
thrombosis and pulmonary embolism, while vertebral fractures can affect pulmonary function 
and cause chronic back pain [221-225]. These findings further stress the importance of 
preventing bone fractures in breast cancer patients in order to improve the overall prognosis. 
6.2.4 Study IV 
We found breast cancer patients to be at increased risk of being hospitalized with an infection 
for up to 10 years since diagnosis, as compared with the general population. Two possible 
explanations of this finding are cancer-induced immunosuppression and treatment-related 
adverse effects as they both seem to play a role in infectious disease susceptibility. Recent 
molecular studies showed that cancer cells can disrupt the host immune surveillance and that 
the interplay between immune components and cancer cells is crucial for disease progression 
[226, 227]. As for treatment, short-term suppression of neutrophil production is a well-known 
side effect of chemotherapy; also, chemotherapy and radiotherapy can impair mucosal 
immunity, and local flora may invade once the physical barrier of epithelial lining is damaged 
[130, 228].  
The increased risk of being hospitalized with an infection was particularly referred to skin 
infections and sepsis, and this is in accordance with two related complications commonly 
observed in breast cancer patients: lymphedema and neutropenia [229, 230]. Approximately 
30% of breast cancer patients develop lymphedema within 18 months after diagnosis [229]. 
Lymphedema can actually cause skin infections [231] and this explains the excess risk found 
for this specific type of infection. The observed overlap in risk factor profile (in terms of 
tumor characteristics, chemotherapy and axillary radiation) reflects the close correlation 
between lymphedema and skin infections [232]. Our results also complement previous work 
showing that erysipela is the most common clinical presentation of skin infections in breast 
cancer patients [233]. Erysipela is an inflammatory cellulitis of the upper dermis usually 
caused by streptococcal infections [234]. If left untreated, it can spread through lymphatic 
vessels and cause severe vessel injury (i.e. lymphangitis), and possibly sepsis as well [233, 
234]. Neutropenia is also closely associated with the risk of sepsis as a common complication 
of chemotherapy [130].  
Several markers of disease severity (including tumor size, grade, lymph node and ER status) 
were associated with the risk of being hospitalized with an infection, and in particular with 
the risk of sepsis. A significant association with lymph node status was previously reported in 
concordance with what we found [134]. The risk of being hospitalized with an infection was 
higher in women diagnosed at age less than 50 years and this could be explained by the fact 
that young breast cancer patients are often diagnosed with a more advanced disease and tend 
to receive more aggressive treatment. 
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Breast cancer patients from our study population were also at increased risk of dying after a 
being hospitalized with an infection as compared with the general population. Therefore, 
averting infections may also improve overall survival of women with breast cancer. 
 
6.3 CONCLUSIONS 
In this thesis we looked at some of the main health outcomes in women with breast cancer 
with a particular focus on the long-term outlook. We investigated the time-dependent effect 
of tumor characteristics and age on overall survival and on specific causes of death. We also 
studied the risk of developing distant recurrences according to different tumor characteristics 
and looked at specific sites of metastasis as well. We finally analyzed the occurrence of two 
common causes of hospitalization, bone fractures and infections, in breast cancer patients, 
and investigated their association with age and tumor characteristics among breast cancer 
patients. After performing the four studies these are our main conclusions: 
- The effects of different tumor characteristics on the risk of distant recurrence and death 
in women with breast cancer significantly change over time since diagnosis. 
- Women with positive lymph nodes at diagnosis carry a worse long-term overall 
prognosis compared with lymph node negative patients; this is not only true in terms of 
overall survival and risk of distant recurrence, but also in terms of hospitalizations for 
common complications like bone fractures and infections.  
- ER status is a strong independent predictor of distant recurrence-free survival and overall 
survival in the first 5 years after breast cancer diagnosis but not any further.  
- ER-positive patients seem to have a low but persistent risk of distant recurrences and 
death and should therefore be appropriately treated and monitored.  
- The risk of distant metastasis is non negligible even after 5 years since breast cancer 
diagnosis in most subgroups of patients. 
- Tumors larger than 20mm at breast cancer diagnosis significantly increase the risk of 
dying, in particular shortly after diagnosis, and of distant recurrences within 10 years 
from diagnosis. 
- Causes of death other than breast cancer are reported in more than 50% of breast cancer 
patients, diagnosed after the age of 65 years, within 10 years since diagnosis.  
- Women with breast cancer are at significantly increased risk of being hospitalized with a 
bone fracture or with an infection for at least 10 years since diagnosis.  
- Tumor characteristics do not differentially affect the risk of being hospitalized with a 
bone fracture. 
- Women with breast cancer are at increased risk of dying after being hospitalized with a 
bone fracture or with an infection.  
- Sepsis and skin infection are the most commonly reported causes of hospitalization due 
to an infection in our study population of women with breast cancer.  
- The risk of being hospitalized with an infection is positively associated with more 
aggressive/advanced tumor characteristics at diagnosis in breast cancer patients.  
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- Preventive measures for bone fractures and infections could be taken into considerations 
for all patients at increased risk.  
- Thanks to remarkable improvements in prognosis, overall survival should not be the only 
main indicator for the management of breast cancer patients. 
- There is no evidence for discontinuation of clinical follow-up of breast cancer patients.  
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7 FUTURE PERSPECTIVES 
The increasing understanding of the molecular mechanisms of breast cancer is going to lead 
to more targeted treatment and may even allow potential individualized approaches in the 
future. The growing availability of molecular information can also contribute to shed 
additional light on the prognosis of different breast cancer subtypes, so that also clinical 
follow-up may become tailored according to the personal outlook of the patient [235-238]. 
Attempts to develop composite prognostic scores for breast cancer are in fact already 
undergoing [239].  
As much as molecular profiles of breast cancer influence prognosis and likelihood of distant 
recurrence [54, 55, 240, 241], also gene expression profiles of breast tumors could be used in 
the next future for the prediction of local and distant patterns of spreading, and as potential 
candidate targets for the development of new drugs [242-246]. Three areas of primary 
research interest are the full identification of comprehensive molecular portraits of breast 
tumors, the influence of the microenvironment and of the stromal tissue on local and distant 
cancer development, and the interaction between cancer and the immune system of the host. 
In particular, the understanding through genome-wide association studies of how the genetic 
predisposition can affect late relapses, non-breast cancer related health outcomes, and even 
potential markers of breast cancer prognosis, would be of considerable clinical relevance. A 
recent study found that a 20% decrease in mammographic breast density in women treated 
with tamoxifen is associated with an improved 15-year survival [27]. Moreover, some studies 
reported that bone mineral density, which is known to be inversely associated with the risk of 
breast cancer [247, 248], may be also associated with prognosis [249]. Finally, changes in 
breast density during breast cancer treatment might be possibly related to changes in bone 
mineral density [250]. In this case, bone mineral density could be evaluated as a potential 
additional marker of late relapses, and breast density as a potential indicator of the risk of 
bone fractures in women with breast cancer.  
Improving the capacity to correctly identify subgroups of breast cancer patients at prolonged 
low risk of recurrence could also spare women from part of the cancer treatment and thus 
decrease their risk of long-term adverse events from the therapy. Furthermore, this could also 
potentially save some of the ever increasing cost associated with treatment of breast cancer. 
The cost of oncologic drugs is remarkably increasing over time going from less than 10,000 
dollars per patient in the early 2000s up to 30,000-50,000 dollars per patient in 2011, 
amounting to at least 5,000 dollars per month or per cycle [251]. On the other hand, new 
targeted drugs, when truly effective, may save a lot of resources by effectively curing patients 
and preventing complications of breast cancer and of adverse effects of current adjuvant 
treatment. Regardless of the national policies in place, the fast increasing cost of oncologic 
technologies for diagnosis and treatment cannot be ignored and need to be incorporated in 
cost-benefit analyses performed with sound health technology assessment’s methodology. 
This evaluation should be however carried out after correctly assessing drug effectiveness by 
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performing well-designed comparative trials with the existing drugs (and not just studies of 
non-inferiority) and by using appropriate end points (and not just surrogate ones). 
The remarkable improvements in survival and the future further achievements should also 
draw more research and attention to the quality of life of breast cancer patients. In particular, 
endocrine, circulatory, psychological and neurological disorders are areas of major clinical 
interest. The treatment of an oncologic patient should never be considered the exclusive 
pertinence of a specialist but a team effort of different professionals putting the patient, and 
not the disease alone, at the center of the clinical care. This implies an organizational 
structure allowing for an oncologic treatment tailored for each specific type of patient, and 
not separately suiting different clinical specializations. Finally, patients should be more 
involved in the decision making concerning breast cancer treatment, and the development of 
new guidelines should always take cost-benefit and patient perspective into consideration. 
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